Retour

Explorez tous les épisodes du podcast Hospital Medicine Unplugged

Plongez dans la liste complète des épisodes de Hospital Medicine Unplugged. Chaque épisode est catalogué accompagné de descriptions détaillées, ce qui facilite la recherche et l'exploration de sujets spécifiques. Suivez tous les épisodes de votre podcast préféré et ne manquez aucun contenu pertinent.

Rows per page:

1–50 of 156

TitreDateDurée
Mixed Connective Tissue Disease in the Hospitalized Patient: Anti-U1 RNP, Overlap Syndromes, and the Lungs That Kill03 Jun 202600:33:54

In this episode of Hospital Medicine Unplugged, we unpack mixed connective tissue disease—recognize the overlap syndrome hiding between lupus, scleroderma, and myositis, and aggressively monitor the pulmonary complications that drive morbidity and mortality.

MCTD is defined by high-titer anti-U1 RNP antibodies plus overlapping connective tissue disease features. The hallmark clues: • Raynaud phenomenon • Swollen hands • Sclerodactyly • Inflammatory arthritis • Myositis • GERD and esophageal dysmotility

Raynaud’s is often the earliest manifestation, and scleroderma-type findings help distinguish MCTD from lupus in anti-RNP–positive patients.

The major threat is pulmonary disease: • Interstitial lung disease (ILD) • Pulmonary arterial hypertension (PAH)

PAH remains the leading cause of death, making routine pulmonary surveillance essential: • Pulmonary function tests with DLCO • High-resolution CT when indicated • Echocardiography for PAH screening

Treatment depends on organ involvement: • Steroids for inflammatory flares • Mycophenolate, methotrexate, or cyclophosphamide for ILD and systemic disease • Rituximab for refractory cases

For MCTD-associated PAH: • Endothelin receptor antagonists • PDE-5 inhibitors • Prostacyclin pathway therapy • Immunosuppression may help more than in systemic sclerosis–associated PAH.

Key pearl: many patients achieve remission or stable disease, but up to one-quarter eventually evolve into a more defined connective tissue disease—most commonly systemic sclerosis or lupus.

We close with the system moves: don’t dismiss Raynaud’s plus swollen hands as “nonspecific,” screen aggressively for ILD and PAH, trend pulmonary function over time, and recognize that lung complications—not arthritis—determine long-term outcomes in MCTD.

The antibody may define the diagnosis, but the lungs define the prognosis.

Myelodysplastic Syndromes in the Hospitalized Patient: Clonal Cytopenias, Risk Stratification, and When to Transplant01 Jun 202600:57:02

In this episode of Hospital Medicine Unplugged, we break down myelodysplastic syndromes—recognize the unexplained cytopenias, understand the modern molecular classification, and risk-stratify patients before progression to AML.

The WHO 2022 classification shifted MDS from a purely morphologic disease to a genetically informed diagnosis. New entities include MDS with SF3B1 mutation, isolated del(5q), and biallelic TP53-mutated MDS, one of the highest-risk subtypes. Blast categories are now simplified into low blasts, increased blasts-1 (5–9%), and increased blasts-2 (10–19%).

Diagnosis requires: • Persistent cytopenias • Dysplasia in >10% of a marrow lineage or defining cytogenetic abnormalities • Exclusion of alternative causes

Bone marrow biopsy remains essential, and unexplained cytopenias with clonal mutations that don’t meet MDS criteria are now classified as CCUS.

Risk stratification centers on the IPSS-R, incorporating: • Cytogenetics • Blast percentage • Hemoglobin • Platelets • Neutrophil count

Lower-risk disease focuses on symptom control and transfusion reduction. Higher-risk disease focuses on delaying AML transformation and improving survival.

For anemia in lower-risk MDS: • ESAs remain common first-line therapy • Luspatercept is especially effective in SF3B1-mutated or ring sideroblast disease and outperformed epoetin alfa in recent trials.

For higher-risk disease: • Azacitidine is standard frontline therapy and improves overall survival • Decitabine is an alternative • Oral decitabine-cedazuridine allows outpatient treatment

Key pearl: responses to hypomethylating agents are delayed—patients often need at least 4–6 cycles before declaring failure.

The only curative therapy is allogeneic stem cell transplantation: • Consider for higher-risk disease and select lower-risk patients with severe cytopenias or poor-risk mutations • Reduced-intensity conditioning expanded transplant eligibility into older adults • TP53-mutated disease remains particularly challenging, even after transplant

We close with the system moves: investigate unexplained macrocytic anemia and cytopenias early, integrate molecular testing into diagnosis and prognosis, avoid prematurely stopping hypomethylating therapy, and refer transplant-eligible patients before progression to AML.

Not every pancytopenia is “just aging marrow”—sometimes it’s a clonal stem-cell disorder announcing itself before leukemia arrives.

Cardiac Amyloidosis in the Hospitalized Patient: The HFpEF Diagnosis You’re Missing29 May 202600:30:17

In this episode of Hospital Medicine Unplugged, we unpack cardiac amyloidosis—recognize the red flags hiding inside “routine HFpEF,” diagnose ATTR noninvasively, and start disease-modifying therapy before restrictive physiology becomes irreversible.

ATTR cardiac amyloidosis is far more common than previously recognized, especially in older adults with HFpEF and increased LV wall thickness. Key clues include voltage-mass discordance—thick ventricles on echo with surprisingly low ECG voltage—and extracardiac findings like carpal tunnel syndrome, lumbar spinal stenosis, trigger finger, or biceps tendon rupture that may precede diagnosis by years.

Echo pearls: • Increased wall thickness with preserved EF • Restrictive filling pattern • Biatrial enlargement • Classic “apical sparing” strain pattern

The modern diagnostic breakthrough is nuclear imaging: • Grade 2–3 uptake on technetium-PYP scan + negative monoclonal protein testing = essentially diagnostic for ATTR-CM without biopsy.

Never skip monoclonal protein screening: • Serum free light chains • Serum immunofixation • Urine immunofixation

This distinction matters because AL amyloidosis is a hematologic emergency requiring plasma-cell–directed therapy.

Treatment changed dramatically with tafamidis: • Reduces mortality • Lowers cardiovascular hospitalizations • Works best when started early

Acoramidis joined the field in 2024 as another TTR stabilizer with similar benefits.

Heart failure management is different here: • Loop diuretics are the backbone • ACE inhibitors, ARBs, and beta-blockers are often poorly tolerated • Avoid digoxin and non-dihydropyridine calcium channel blockers

Key pearl: anticoagulate atrial fibrillation regardless of CHA₂DS₂-VASc score due to extreme thromboembolic risk.

We close with the system moves: when HFpEF doesn’t quite fit—especially with unexplained LVH, neuropathy, orthopedic history, or voltage-mass discordance—think amyloid early, order monoclonal protein studies plus PYP scanning, and start disease-modifying therapy before fibrosis and restrictive failure dominate the trajectory.

Not all HFpEF is hypertensive heart disease—sometimes the diagnosis is hiding in the carpal tunnel scar.

Sarcoidosis in the Hospitalized Patient: Multisystem Granulomas and the Organs You Can’t Miss27 May 202600:40:32

In this episode of Hospital Medicine Unplugged, we tackle sarcoidosis—recognize the classic presentations, screen aggressively for silent organ involvement, and treat the patients at highest risk for irreversible damage or sudden death.

Diagnosis requires three things: compatible clinical presentation, non-caseating granulomas, and exclusion of alternative granulomatous disease like TB, fungal infection, or malignancy. Some syndromes are classic enough to skip biopsy, including Löfgren syndrome (bilateral hilar adenopathy, erythema nodosum, arthritis, fever) and lupus pernio. Most hospitalized patients, though, need tissue confirmation—typically via EBUS-guided transbronchial needle aspiration for intrathoracic lymphadenopathy.

Once diagnosed, the mission shifts to multisystem screening: • Pulmonary: chest imaging + PFTs with DLCO • Cardiac: ECG for all patients; cardiac MRI or FDG PET for symptoms, arrhythmias, or conduction disease • Ophthalmologic: slit-lamp examination • Labs: CBC, creatinine, calcium, alkaline phosphatase, vitamin D metabolites when indicated

Cardiac sarcoidosis is a major killer and can present with AV block, ventricular arrhythmias, syncope, or unexplained cardiomyopathy. Neurosarcoidosis can cause cranial neuropathies, meningitis, seizures, or spinal cord disease—both require aggressive recognition and treatment.

Not all sarcoidosis needs therapy. Treat when there’s risk of organ damage, death, or severe symptoms: • Cardiac sarcoidosis • Neurosarcoidosis • Progressive pulmonary disease • Ocular disease • Symptomatic hypercalcemia

Treatment backbone: • Prednisone 20–40 mg/day for most disease • Higher-dose steroids for cardiac/neuro involvement • IV methylprednisolone for life-threatening presentations

Steroid-sparing therapy matters early: • Methotrexate is the preferred second-line agent • Azathioprine, mycophenolate, and leflunomide are alternatives • Infliximab or other biologics for refractory disease

Cardiac sarcoidosis often needs more than immunosuppression: • ICDs for ventricular arrhythmia risk • Pacemakers for conduction disease • Catheter ablation for refractory VT

Key inpatient pearls: • Monitor calcium and steroid toxicity • Use telemetry if cardiac involvement suspected • Watch for progressive hypoxemia or arrhythmias • Involve pulmonology, cardiology, ophthalmology, and neurology early

We close with the system moves: build a standardized sarcoidosis screening pathway, default to ECG + pulmonary testing + ophthalmology evaluation at diagnosis, escalate rapidly to cardiac imaging when red flags appear, and initiate steroid-sparing therapy early for chronic disease.

Granulomas are only the start—screen every organ, respect cardiac sarcoidosis, and treat before inflammation becomes permanent fibrosis.

Autoimmune Encephalitis in a Hospitalized Patient: Diagnose Early, Treat Fast, Recover Long25 May 202600:55:27

In this episode of Hospital Medicine Unplugged, we unpack autoimmune encephalitis—recognize the red flags early, treat aggressively before antibody results return, and support the long recovery arc that often extends years beyond discharge.

We open with the bedside reality: autoimmune encephalitis is frequently missed because it masquerades as psychiatry, infection, toxic-metabolic disease, or unexplained delirium. The key clue is rapid progression over days to weeks with combinations of psychiatric symptoms, memory loss, seizures, dyskinesias, autonomic instability, speech dysfunction, or decreased consciousness.

Diagnosis starts clinically—not with waiting for antibodies. The Graus 2016 framework emphasizes a tiered approach using history, exam, MRI, EEG, CSF, and syndrome recognition. For anti-NMDA receptor encephalitis, probable diagnosis requires rapid onset (<3 months) of at least four major symptom groups (psychiatric/cognitive dysfunction, speech dysfunction, seizures, movement disorder, decreased consciousness, autonomic dysfunction) plus abnormal EEG or CSF findings—or three symptom groups with a teratoma identified. Normal MRI does not exclude disease.

Core diagnostic workup: • MRI brain with and without contrast • EEG (often diffuse slowing or extreme delta brush in anti-NMDAR disease) • Lumbar puncture with CSF cell count, protein, oligoclonal bands, infectious PCRs, autoimmune panels • Serum + CSF neuronal antibody testing • Broad infectious exclusion—especially HSV encephalitis • Tumor screening (ovarian teratoma, thymoma, small-cell lung cancer, etc.)

The critical management principle: do not delay immunotherapy waiting for antibodies. Seronegative autoimmune encephalitis exists, testing sensitivity is imperfect, and treatment delay worsens outcomes.

First-line therapy builds the immunotherapy backbone: • High-dose corticosteroids • IVIG • Plasma exchange (PLEX)

Evidence increasingly favors combination therapy over isolated treatment. Meta-analysis data from >1,500 patients showed therapeutic apheresis alone or combination regimens (steroids + IVIG or all three modalities) had the best odds of favorable recovery. Failure to initiate immunotherapy within 30 days was associated with markedly worse outcomes.

If first-line treatment stalls: • Rituximab becomes the preferred second-line agent • Cyclophosphamide remains an option in refractory disease • Escalation should happen early in severe or persistent cases rather than waiting months

Rituximab deserves special attention—it not only improves refractory disease but also substantially lowers relapse risk, with studies demonstrating nearly a six-fold reduction in recurrence odds.

ICU pearls you don’t want to miss: • Autonomic instability can become life-threatening • Refractory seizures and status epilepticus are common • Dyskinesias may require deep sedation • Ventilator dependence is frequent in severe anti-NMDAR disease • Always continue aggressive rehabilitation planning early

Tumor search is not optional: • Ovarian teratoma in young women with anti-NMDAR encephalitis • Thymoma in LGI1/CASPR2 syndromes • Small-cell lung cancer in classic paraneoplastic syndromes

When present, tumor removal is treatment and significantly affects relapse risk and neurologic recovery.

Recovery is where expectations need recalibration. Improvement is often slow, nonlinear, and incomplete despite “good” functional scores. About 75–81% of anti-NMDAR patients eventually achieve substantial recovery, but progress may continue for 24–36 months. The largest gains occur in the first 6 months, yet persistent deficits in memory, language, fatigue, emotional health, and social functioning are extremely common.

One of the most important recent observations: autoimmune encephalitis patients continue improving well beyond the timeline expected for infectious encephalitis. Critically ill autoimmune cases may show functional gains throughout the entire first year, reinforcing the importance of prolonged rehab and longitudinal neurologic support.

Relapse prevention matters: • Relapse occurs in roughly 12–25% • Risk rises when tumors are not removed or second-line immunotherapy is omitted • Rituximab is increasingly used as relapse-prevention therapy in high-risk patients

Pediatric disease brings additional nuance: • Behavioral and psychiatric presentations dominate early • Earlier immune treatment correlates with better outcomes • Cognitive recovery trajectories differ from adults and may evolve over years

We close with the system moves: (1) build an encephalitis pathway that triggers simultaneous infectious + autoimmune evaluation; (2) default to early EEG, CSF, MRI, and antibody panels; (3) begin empiric immunotherapy when suspicion is high; (4) create automatic malignancy-screening pathways; (5) escalate rapidly to rituximab when first-line response is incomplete; (6) embed rehab, neuropsychology, psychiatry, and family support early; (7) follow patients longitudinally because recovery continues long after discharge.

Fast recognition, early immunotherapy, aggressive escalation, and long-term rehabilitation—autoimmune encephalitis is treatable, but only if you think about it before the antibodies come back.

Acute Interstitial Nephritis in the Hospitalized Patient: Drug-Induced AKI and Modern Diagnosis20 Apr 202600:48:18

In this episode of Hospital Medicine Unplugged, we unpack acute interstitial nephritis (AIN)—a frequently overlooked cause of acute kidney injury (AKI) driven largely by medications, immune reactions, and systemic diseases.

We start with epidemiology clinicians should recognize. AIN accounts for roughly 15–27% of kidney biopsies performed for AKI and about 2.8% of all kidney biopsies overall. Among biopsies done specifically for acute renal failure, AIN represents ~13.5% of cases. Drug-induced AIN dominates the landscape, responsible for 70–90% of biopsy-proven cases, and its incidence appears to be rising—particularly in older adults, where polypharmacy and underutilization of kidney biopsy can obscure the diagnosis.

Next we break down the most common causes. • Antibiotics are the leading class, responsible for ~49% of drug-induced AIN, especially penicillins, cephalosporins, rifampin, and fluoroquinolones. • Proton pump inhibitors account for ~14%, with omeprazole the single most common culprit drug. • NSAIDs (~11%) are another major contributor. Other causes include 5-aminosalicylates, diuretics, allopurinol, anticonvulsants, and chemotherapeutic agents. Emerging causes include immune checkpoint inhibitors, reflecting the expanding use of immunotherapy in oncology.

We then explore the immunologic pathophysiology. AIN is primarily driven by T-cell–mediated hypersensitivity reactions (Type IV) targeting tubular antigens or drug-related antigens processed by tubular epithelial cells. However, IgE-mediated mast cell activation (Type I hypersensitivity) may also contribute in some cases. The resulting interstitial inflammation and edema can rapidly progress to fibrosis, making early recognition and treatment critical for renal recovery.

Histologically, AIN is characterized by interstitial inflammatory infiltrates composed mainly of lymphocytes, macrophages, plasma cells, and sometimes eosinophils, along with tubulitis, interstitial edema, and tubular injury. Glomeruli are typically normal, while interstitial fibrosis and tubular atrophy signal chronicity and worse prognosis. Variants include granulomatous AIN and rare entities like IgM-positive plasma cell tubulointerstitial nephritis.

Clinically, the classic triad of fever, rash, and eosinophilia is now uncommon—present in fewer than 10–15% of patients. Instead, most patients present with nonspecific symptoms such as malaise, nausea, or asymptomatic AKI. Non-oliguric AKI is typical, often accompanied by mild proteinuria and tubular dysfunction.

Diagnosis relies on clinical suspicion, medication review, and supportive laboratory findings. Urinalysis may show sterile pyuria and white blood cell casts, which are more specific for AIN. Eosinophiluria, historically emphasized, is neither sensitive nor specific. Ultimately, kidney biopsy remains the gold standard when the diagnosis is uncertain.

We also review emerging biomarkers that may transform diagnosis. Urinary CXCL9, an interferon-γ–induced chemokine involved in lymphocyte recruitment, has shown excellent diagnostic performance with AUC values up to ~0.94 for AIN detection. Additional candidate biomarkers include urinary TNF-α, IL-9, kidney injury molecule-1 (KIM-1), and soluble C5b-9, reflecting tubular injury and immune activation.

Management begins with immediate withdrawal of the offending drug. If kidney function does not improve within 5–7 days, corticosteroid therapy is often initiated, typically prednisone ~40–60 mg daily (~0.8 mg/kg). Evidence suggests that early steroid therapy—within the first 1–2 weeks—improves renal recovery, while prolonged treatment beyond several weeks offers little additional benefit.

Finally, we discuss prognosis. About 76% of patients achieve some degree of kidney recovery within six months, with complete recovery in roughly half of steroid-treated cases. However, chronic kidney disease remains common, and long-term studies suggest up to 39% of patients may eventually develop end-stage kidney disease. Poor outcomes are associated with delayed diagnosis, prolonged drug exposure, interstitial fibrosis on biopsy, dialysis requirement, and older age.

The key takeaway: acute interstitial nephritis is a common, often medication-related cause of AKI that requires high clinical suspicion, prompt withdrawal of offending drugs, and early consideration of corticosteroids to prevent irreversible kidney damage.

Celiac Disease in the Hospitalized Patient: Diagnosis, Complications, and the Future Beyond Gluten-Free Diets17 Apr 202601:03:59

In this episode of Hospital Medicine Unplugged, we break down celiac disease—from epidemiology and modern diagnostic strategies to life-threatening complications and emerging therapies beyond the gluten-free diet.

We start with epidemiology clinicians should know. The global prevalence of celiac disease is ~1.4% based on serology and ~0.7% with biopsy confirmation. Incidence rates are ~17 per 100,000 person-years in women and ~8 per 100,000 in men, with a female-to-male ratio of ~1.8. Importantly, about 70% of cases remain undiagnosed, the so-called “celiac iceberg.” Over recent decades, incidence has increased substantially, rising from <2 per 100,000 annually in the 1980s to >20 per 100,000 in many regions today.

Next we unpack genetic susceptibility and immune pathogenesis. Nearly all patients carry HLA-DQ2 or HLA-DQ8, but these genes alone are insufficient—~40% of the population carries them, yet only 1–3% develop disease, highlighting the role of environmental triggers and additional genetic factors. Gluten exposure leads to immune activation against deamidated gliadin peptides, resulting in small-intestinal inflammation, villous atrophy, and malabsorption.

We then highlight how the clinical presentation has shifted. The classic picture of malabsorption with diarrhea and weight loss is now less common in adults. Instead, non-classical presentations predominate, including iron-deficiency anemia, osteoporosis, abnormal liver enzymes, infertility, and nonspecific GI symptoms. Diarrhea still occurs in ~40–50% of patients, but many adults present with extraintestinal manifestations or even asymptomatic disease.

We also review celiac crisis, a rare but life-threatening presentation requiring hospitalization. Patients develop severe diarrhea, dehydration, electrolyte disturbances, metabolic acidosis, and profound malnutrition. Management requires intravenous fluids, electrolyte replacement, aggressive nutritional support, and sometimes corticosteroids, alongside initiation of a strict gluten-free diet, which leads to improvement in the vast majority of patients.

Diagnosis begins with serologic testing. IgA tissue transglutaminase (tTG-IgA) is the preferred initial screening test, with ~93–95% sensitivity and ~95–98% specificity, and total IgA should be measured simultaneously to detect IgA deficiency. Endomysial antibody testing has near-100% specificity and can confirm the diagnosis. In adults, upper endoscopy with small-bowel biopsy remains the diagnostic standard, demonstrating intraepithelial lymphocytosis, crypt hyperplasia, and villous atrophy.

We then discuss major complications clinicians must recognize. These include osteoporosis, infertility, neurologic complications, hyposplenism, and small-bowel adenocarcinoma. One of the most serious is enteropathy-associated T-cell lymphoma (EATL)—a rare but aggressive malignancy with very poor survival, often arising from type 2 refractory celiac disease.

Refractory celiac disease (RCD) occurs when symptoms and villous atrophy persist despite ≥12 months of strict gluten-free diet. • Type 1 RCD behaves similarly to active celiac disease and responds to immunosuppressive therapy with excellent survival. • Type 2 RCD represents a pre-lymphoma state with clonal abnormal lymphocytes, and 30–50% progress to EATL within five years.

Management still centers on the gluten-free diet, which leads to symptomatic improvement in ~70% of patients within two weeks, though histologic healing can take months and may remain incomplete in many adults.

Finally, we explore the future of therapy. While diet remains the cornerstone, multiple pharmacologic strategies are in development, including gluten-degrading enzymes, intestinal barrier modulators like larazotide, transglutaminase inhibitors, immune-modulating therapies targeting IL-15, microbiome-based therapies, and even gene-edited wheat with reduced immunogenic gluten.

The takeaway: celiac disease is common, frequently underdiagnosed, and increasingly recognized through non-classical presentations. With improved diagnostics, recognition of severe complications like refractory disease and lymphoma, and a rapidly evolving therapeutic pipeline, management of celiac disease is entering a new era beyond diet alone.

Polypharmacy & Deprescribing in the Hospitalized Patient: Safer Medication Use in Older Adults15 Apr 202600:44:10

In this episode of Hospital Medicine Unplugged, we tackle polypharmacy and deprescribing—how to recognize problematic medication overload, quantify its harms, and apply structured, patient-centered strategies to safely reduce medication burden.

We begin with definitions that shape clinical practice. Polypharmacy is most commonly defined as the use of ≥5 medications, though definitions vary. Importantly, not all polypharmacy is harmful. “Appropriate polypharmacy” occurs when medications are evidence-based and optimized, while “problematic polypharmacy” arises when medications lack clear benefit or when harms outweigh benefits. Deprescribing is the systematic process of identifying and discontinuing medications whose risks exceed benefits, aligned with a patient’s goals, function, life expectancy, and preferences.

Next we review how common this problem is. Polypharmacy affects 30–40% of community-dwelling older adults, 40–50% of hospitalized older adults, and up to 90% of nursing home residents. Roughly 20–50% of older adults take at least one potentially inappropriate medication (PIM). Risk rises with multimorbidity, female sex, lower socioeconomic status, and each additional chronic disease increases the odds of polypharmacy by nearly 90%.

We then quantify the clinical consequences. • Adverse drug events occur in 20–30% of hospitalized older adults, and each additional medication increases adverse reaction risk by ~10%. • Polypharmacy is associated with higher mortality (HR ~1.2–1.7) and increased hospital admissions and readmissions. • It also increases fall risk (OR ~1.6) and contributes to hip fractures, frailty, cognitive impairment, and functional decline.

A key driver is the prescribing cascade, where a drug causes side effects that are treated with additional medications. Classic examples include: • NSAIDs → hypertension → antihypertensives • Cholinesterase inhibitors → urinary incontinence → anticholinergics • Calcium channel blockers → edema → diuretics • Antipsychotics → parkinsonism → antiparkinsonian drugs

To identify problematic medications, we review major screening tools. • 2023 AGS Beers Criteria highlights medications to avoid or use cautiously in older adults, including guidance on benzodiazepines, antipsychotics in dementia, and aspirin for primary prevention in adults ≥70. • STOPP/START version 3 includes 94 criteria for inappropriate prescriptions and 34 for underprescribing. • Additional tools include the Medication Appropriateness Index, FORTA classification, Anticholinergic Cognitive Burden scale, and Drug Burden Index.

We then walk through a practical deprescribing framework. A common 5-step protocol includes:

  1. List all medications and indications

  2. Assess overall risk of drug-related harm

  3. Identify drugs eligible for discontinuation

  4. Prioritize those with highest harm and lowest benefit

  5. Implement tapering and monitor for withdrawal or recurrence

Certain medications require careful tapering to prevent withdrawal syndromes, including benzodiazepines, beta-blockers, antidepressants, corticosteroids, opioids, antiepileptics, clonidine, baclofen, and proton pump inhibitors.

We highlight high-yield deprescribing targets. • Proton pump inhibitors: up to 70% lack appropriate indication; associated with C. difficile infection, pneumonia, CKD, and fractures. • Benzodiazepines: linked to falls, delirium, and cognitive impairment, with tapering success rates 27–80%. • Antipsychotics: frequently used for dementia behaviors but carry 1.6–1.7× increased mortality risk. • Anticholinergic medications: high burden strongly linked to cognitive decline and mortality. • Sliding-scale insulin: increases hypoglycemia without improving glycemic control.

We also discuss patient and system barriers. Interestingly, 92% of older adults say they would stop at least one medication if their doctor recommended it, though many fear symptom recurrence or believe medications are necessary.

Finally, we examine solutions that work. Pharmacist-led medication reviews reduce inappropriate medications by 21–35% and lower readmissions, while clinical decision support tools in electronic health records can flag high-risk medications and prompt deprescribing conversations.

The takeaway: polypharmacy is common, harmful, and often reversible. Using structured frameworks, validated screening tools, and shared decision-making, clinicians can safely deprescribe and improve medication safety—especially for older adults with multimorbidity.

Primary Hyperparathyroidism in the Hospitalized Patient: Diagnosis, Imaging, and When to Operate13 Apr 202600:39:42

In this episode of Hospital Medicine Unplugged, we break down primary hyperparathyroidism (PHPT)—from epidemiology and pathophysiology to modern imaging, surgical indications, and evolving medical therapies.

We start with who gets PHPT and how often it occurs. The condition affects ~0.8–0.9% of the general population, with an incidence of 4–6 cases per 10,000 person-years. It is 2.5 times more common in women, and incidence rises sharply with age, reaching ~12 cases per 10,000 person-years in people aged 70–79. There are also racial disparities, with higher incidence reported in Black populations.

Next we unpack the causes of PHPT. About 80% of cases result from a single parathyroid adenoma, 10–11% from multiple adenomas, <10% from four-gland hyperplasia, and <1% from parathyroid carcinoma. Some cases occur in genetic syndromes such as MEN1, MEN2A, MEN4, and hyperparathyroidism–jaw tumor syndrome.

Clinically, up to 80% of patients in resource-rich settings are now asymptomatic, discovered incidentally through routine lab testing. When symptoms occur, they reflect hypercalcemia and PTH excess, including kidney stones, osteoporosis, gastrointestinal symptoms, and neuromuscular complaints. Many patients also report fatigue, depression, or cognitive symptoms, though the direct causal relationship remains debated.

We then cover complications that drive treatment decisions. PHPT can lead to osteoporosis, fragility fractures, nephrolithiasis, and reduced kidney function. There is also growing evidence linking PHPT with hypertension, left ventricular hypertrophy, and increased cardiovascular risk, though cardiovascular benefit from surgery remains uncertain.

Diagnosis starts with biochemical confirmation—elevated calcium with inappropriately elevated PTH. Imaging is not for diagnosis but for surgical planning. The usual first-line localization strategy combines neck ultrasound with dual-tracer sestamibi scanning, while second-line imaging options such as 4D-CT or 18F-fluorocholine PET/CT offer extremely high sensitivity—up to ~94–99%.

Management centers on parathyroidectomy, which is the definitive treatment. Current guidelines recommend surgery for patients with: • Serum calcium >1 mg/dL above normal • Age <50 years • Osteoporosis (T-score ≤ −2.5) or vertebral fracture • Kidney disease (eGFR <60) • Hypercalciuria (>250 mg/day in women, >300 mg/day in men) • Kidney stones or nephrocalcinosis • Symptomatic disease

For patients who are not surgical candidates, several medications help control complications: • Cinacalcet lowers serum calcium and PTH but does not improve bone density • Bisphosphonates (like alendronate) improve bone density but do not lower calcium • Denosumab and combination therapy with cinacalcet may help address both hypercalcemia and bone loss

We also explore normocalcemic primary hyperparathyroidism, an increasingly recognized condition defined by elevated PTH with normal calcium after excluding secondary causes. It may represent an early or milder form of PHPT, often with more multiglandular disease and slightly lower surgical cure rates.

Finally, we highlight critical diagnostic pitfalls and emerging research. Distinguishing PHPT from familial hypocalciuric hypercalcemia (FHH) is essential—FHH shows lifelong mild hypercalcemia and a calcium-to-creatinine clearance ratio <0.01 and does not require surgery. Meanwhile, advanced imaging, genetic testing in younger patients, and combination pharmacotherapy are shaping the future of PHPT care.

The bottom line: primary hyperparathyroidism is common, increasingly detected incidentally, and highly treatable—especially when clinicians recognize surgical indications, use modern imaging strategies, and tailor therapy to complications and patient risk.

ANCA Vasculitis: From Pathophysiology to Precision Treatment in the Hospitalized Patient10 Apr 202600:32:10

In this episode of Hospital Medicine Unplugged, we break down ANCA-associated vasculitis (AAV)—granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA)—focusing on modern epidemiology, complement-driven pathophysiology, ANCA serotypes, and the rapidly evolving treatment landscape.

We start with epidemiology clinicians should recognize. The global incidence of AAV is ~17 per million person-years, with a prevalence near 198 per million. In the United States, incidence is roughly 3.3 per 100,000, with a prevalence of ~42 per 100,000. Subtype incidence varies: GPA (~9–15/million), MPA (~6/million), and EGPA (~2/million). The mean age at diagnosis is about 61, and rates have increased over the past decades due to greater recognition and widespread ANCA testing.

Next we unpack the pathophysiology that changed therapy. Complement activation—particularly the alternative pathway—plays a central role. C5a drives neutrophil activation and recruitment, creating an inflammatory amplification loop. Low C3 levels correlate with more aggressive disease and worse renal outcomes. This mechanistic insight led to avacopan, an oral C5a receptor antagonist that provides a glucocorticoid-sparing approach to treatment.

We then highlight the importance of ANCA serotype classification. Patients are increasingly categorized by PR3-ANCA vs MPO-ANCA, not just clinical phenotype. • PR3-ANCA disease is more often GPA, with ENT involvement, pulmonary nodules, and higher relapse risk. • MPO-ANCA disease more often presents as MPA, with renal-limited disease, interstitial lung disease, and higher mortality.

We also review EGPA as a distinct entity. Only ~40% of patients are ANCA-positive. Two clinical subsets exist: • ANCA-positive EGPA → vasculitic manifestations such as glomerulonephritis and neuropathy • ANCA-negative EGPA → eosinophilic disease with pulmonary infiltrates and cardiomyopathy Asthma is a defining feature, and cardiac involvement is a major driver of mortality.

Diagnosis relies on modern ANCA testing and organ evaluation. PR3- and MPO-specific immunoassays are now the preferred screening tests, with ~90–95% sensitivity for active GPA/MPA and >95% specificity. Renal disease occurs in 70–80% of GPA/MPA, typically as pauci-immune necrotizing crescentic glomerulonephritis, while pulmonary disease ranges from nodules and cavitation (PR3) to interstitial lung disease (MPO) and diffuse alveolar hemorrhage.

Management has evolved dramatically. First-line induction therapy combines glucocorticoids with rituximab or cyclophosphamide, with rituximab preferred for most patients—especially PR3-ANCA or relapsing disease. Reduced-dose steroid regimens are now recommended after trials like PEXIVAS, which showed lower infection risk without worse renal outcomes.

We also cover key modern therapies. • Avacopan, a C5a receptor antagonist, improves sustained remission and kidney recovery while reducing steroid exposure. • Plasma exchange remains controversial after the PEXIVAS trial, but may still be considered in severe kidney failure, dialysis-dependent disease, or diffuse alveolar hemorrhage.

For maintenance therapy, rituximab is now the preferred agent, outperforming azathioprine in major trials such as MAINRITSAN and RITAZAREM. Maintenance typically continues 2–4 years, especially in PR3-ANCA patients with high relapse risk.

We finish with EGPA-specific treatment advances. IL-5 pathway inhibitors have transformed care, including mepolizumab and the newer benralizumab, which improve remission rates and allow significant glucocorticoid reduction.

The bottom line: AAV management has shifted toward precision medicine—ANCA serotype classification, complement-targeted therapy, steroid-sparing strategies, and biologic maintenance treatments—dramatically improving survival and long-term outcomes.

Clinical Management and Metabolism of Fat-Soluble Vitamins in the Hospitalized Patient08 Apr 202600:29:01

In this episode of Hospital Medicine Unplugged, we sprint through fat-soluble vitamins—A, D, E, and K—focusing on how they’re absorbed, why deficiencies happen, and the clinical syndromes hospitalists must recognize early. From intestinal transporters to neurologic deficits and neonatal bleeding, we connect physiology to bedside decision-making.

We start with absorption mechanics, which are more complex than simple passive diffusion. Modern research shows specific intestinal transporters—SR-BI, CD36, NPC1L1, and ABCA1—facilitate uptake of vitamins D, E, and K. Interestingly, vitamin A appears to lack a dedicated membrane transporter for dietary absorption. Absorption is also competitive: vitamins D, E, and K compete with one another, while vitamin A can suppress absorption of other fat-soluble vitamins without being affected itself. This interaction becomes clinically relevant in patients taking high-dose supplements.

Next we tackle vitamin A—vision, epithelial integrity, and immune defense.

Deficiency follows a classic progression: • Night blindness (earliest symptom) • Xerophthalmia • Bitot spots • Irreversible corneal damage and blindness

Vitamin A also regulates epithelial differentiation and T-cell immune function, so deficiency increases susceptibility to infection. Even in high-income settings, restrictive diets or selective eating can lead to severe deficiency and permanent ocular injury.

Toxicity is equally important. Chronic hypervitaminosis A causes: • Elevated intracranial pressure (headache, vomiting, papilledema, bulging fontanelle in infants) • Hepatotoxicity • Bone abnormalities from vitamin D receptor antagonism • Teratogenic effects

Sustained doses around 50,000 IU daily for >18 months can produce chronic toxicity.

We then shift to vitamin D—arguably the most clinically debated fat-soluble vitamin.

Vitamin D metabolism follows a three-step pathway:

  1. UVB exposure converts 7-dehydrocholesterol in skin to vitamin D3

  2. Hepatic conversion to 25-hydroxyvitamin D (calcidiol)

  3. Renal activation to calcitriol (1,25-dihydroxyvitamin D)

This active hormone regulates calcium and phosphate homeostasis through tight feedback with parathyroid hormone.

Deficiency is widespread—over one billion people globally. Classic consequences include rickets in children and osteomalacia or osteoporosis in adults, but deficiency also contributes to proximal muscle weakness, increasing fall and fracture risk.

Vitamin D receptors are expressed throughout the body, and observational data link deficiency with cardiovascular disease, autoimmune disease, diabetes, multiple sclerosis, and cancer, although randomized trials show mixed results for extraskeletal benefits.

A key clinical debate remains optimal levels. Many experts advocate serum 25-hydroxyvitamin D concentrations above 40–50 ng/mL, often requiring supplementation beyond traditional recommendations.

Next up: vitamin E—the neurologic protector.

Deficiency primarily manifests with neurologic disease, including: • Peripheral neuropathy • Cerebellar and sensory ataxia • Posterior column dysfunction • Hyporeflexia • Oculomotor abnormalities such as impaired upward gaze

Severe cases can progress to blindness and dementia.

In cholestatic patients, interpretation requires nuance. Vitamin E levels may appear falsely normal due to hyperlipidemia, so clinicians should measure the vitamin E–to–total lipid ratio instead. Another diagnostic clue is red blood cell acanthocytosis on blood smear.

Toxicity is uncommon but high-dose vitamin E increases bleeding risk, particularly in patients taking anticoagulants.

We close with vitamin K—the coagulation vitamin with expanding roles in vascular biology.

Vitamin K enables γ-carboxylation of clotting factors II, VII, IX, and X and anticoagulant proteins C and S. Deficiency produces functional clotting factor impairment and bleeding once levels fall below ~30 U/dL.

In neonates, vitamin K deficiency bleeding (VKDB) occurs in three forms: • Early (<24 hours) – linked to maternal medications • Classic (2–7 days) • Late (1–3 months) – the most dangerous, with >50% presenting with intracranial hemorrhage

Routine intramuscular vitamin K prophylaxis at birth prevents nearly all cases of late VKDB.

Beyond coagulation, vitamin K activates matrix Gla protein, a powerful inhibitor of vascular calcification, and osteocalcin, which supports bone metabolism.

We also spotlight high-risk populations for fat-soluble vitamin deficiency, including patients with: • Cholestatic liver disease • Chronic pancreatitis and pancreatic insufficiency • Inflammatory bowel disease or celiac disease • Cystic fibrosis • Bariatric surgery • Genetic lipid disorders such as abetalipoproteinemia or α-TTP deficiency

Certain medications impair absorption as well—orlistat, cholestyramine, and long-term antibiotics.

Finally, we review laboratory assessment strategies that actually work.

• Vitamin A: serum retinol 1–3 μmol/L normal • Vitamin D: 25-hydroxyvitamin D is the standard marker • Vitamin E: use vitamin E–to–lipid ratio in cholestasis • Vitamin K: measure phylloquinone or PIVKA-II (undercarboxylated prothrombin)—because PT/aPTT are insensitive for early deficiency

Bottom line: fat-soluble vitamins depend on lipid absorption, specialized transporters, and intact hepatobiliary and pancreatic function. Recognizing malabsorption states, neurologic or ocular clues, and appropriate biomarkers is essential to diagnosing deficiency early—before irreversible complications like blindness, neuropathy, fractures, or intracranial hemorrhage occur.

Thalassemias: Genetics, Pathophysiology, and Clinical Manifestations in the Hospitalized Patient06 Apr 202600:35:43

In this episode of Hospital Medicine Unplugged, we sprint through thalassemia—an inherited hemoglobinopathy defined by reduced or absent globin chain production, ineffective erythropoiesis, and chronic anemia. We break down the genetics, pathophysiology, clinical spectrum, and why this disorder remains the most common monogenic disease worldwide.

We start with the big picture. About 5% of the global population carries an α-thalassemia allele and 1.5% carries a β-thalassemia allele, with roughly 1.3 million people living with disease and ~40,000 affected infants born annually. The condition clusters across malaria-endemic regions—from sub-Saharan Africa and the Mediterranean to the Middle East, South Asia, and Southeast Asia—because the carrier state provides partial protection against malaria. Migration has increasingly brought thalassemia to North America and Europe, expanding its global clinical impact.

Next, we revisit normal hemoglobin physiology. Adult hemoglobin (HbA) is α₂β₂, with smaller fractions of HbA₂ (α₂δ₂) and HbF (α₂γ₂). During infancy, the body transitions from fetal hemoglobin to adult hemoglobin as γ-globin declines and β-globin production increases, regulated by transcription factors such as BCL11A and KLF1. Balanced α- and β-chain production is essential—when the balance breaks, unpaired globin chains accumulate, precipitate, and damage developing red cells, driving ineffective erythropoiesis.

We then dive into the genetic architecture. α-globin genes (HBA1, HBA2) sit on chromosome 16 with four total copies, while the β-globin gene (HBB) lies on chromosome 11 with two total copies.

• α-thalassemia is usually caused by gene deletions affecting HBA1 or HBA2. • β-thalassemia typically results from point mutations affecting transcription, RNA splicing, or translation.

Mutations are classified as: • β⁰ mutations: no β-globin production • β⁺ mutations: reduced β-globin synthesis

Severity depends on genotype, but genetic modifiers matter—coinherited α-thalassemia, increased HbF production, or α-globin gene duplications can significantly alter disease expression.

Next, we map the clinical classification.

Alpha thalassemia spectrum: • Silent carrier: one gene affected, usually asymptomatic • α-thalassemia trait: two genes affected, mild microcytic anemia • Hemoglobin H disease: three genes affected → moderate-severe hemolytic anemia with β₄ tetramers • Hb Bart’s hydrops fetalis: four genes deleted → incompatible with life

Beta thalassemia spectrum: • β-thalassemia trait: mild microcytic anemia with elevated HbA₂ (>3.5%) • β-thalassemia intermedia: moderate anemia with variable transfusion needs • β-thalassemia major (Cooley anemia): severe disease presenting in infancy requiring lifelong transfusions

Compound disorders add complexity, including HbE-β thalassemia and sickle-β thalassemia, where severity depends on the interacting mutations.

Then we unpack the pathophysiology driving complications.

Excess unpaired globin chains cause oxidative damage and premature death of erythroid precursors, leading to: • Ineffective erythropoiesis with massive marrow expansion • Hemolysis from fragile red cells • Extramedullary hematopoiesis in liver and spleen

Chronic erythropoietin stimulation leads to skeletal deformities—frontal bossing, maxillary hypertrophy, and long-bone abnormalities.

Iron overload develops through two major pathways: • Transfusion iron loading (each unit adds ~200–250 mg of iron) • Increased intestinal absorption from suppressed hepcidin due to ineffective erythropoiesis

The downstream damage is systemic: cardiomyopathy, arrhythmias, liver fibrosis and cirrhosis, endocrine failure (growth delay, diabetes, hypothyroidism, hypoparathyroidism), osteoporosis, and thrombosis risk.

We close with the clinical spectrum.

• Trait: usually asymptomatic with incidental microcytosis • Intermedia: moderate anemia (Hb ~7–10 g/dL), skeletal changes, gallstones, pulmonary hypertension, extramedullary masses • Major: early infancy presentation with severe anemia, failure to thrive, hepatosplenomegaly, and the classic “chipmunk facies” from marrow expansion

Bottom line: thalassemia is a disorder of globin chain imbalance leading to ineffective erythropoiesis, hemolysis, marrow expansion, and iron overload. Understanding the genetics, modifiers, and pathophysiology is essential to predicting severity, guiding transfusion strategies, and preventing the devastating end-organ complications of chronic iron toxicity.

Clinical Guide to Axial Spondyloarthritis and Ankylosing Spondylitis03 Apr 202600:21:43

In this episode of Hospital Medicine Unplugged, we sprint through ankylosing spondylitis and axial spondyloarthritis—recognize inflammatory back pain early, understand the disease spectrum from non-radiographic to radiographic disease, and treat aggressively to prevent structural damage and disability.

We begin with the modern concept of axial spondyloarthritis (axSpA), which represents a disease spectrum rather than a single condition. At one end is non-radiographic axial spondyloarthritis (nr-axSpA)—patients with typical symptoms but without definitive radiographic sacroiliitis. At the other end is radiographic axial spondyloarthritis (r-axSpA), historically known as ankylosing spondylitis, where structural changes in the sacroiliac joints are visible on X-ray.

Globally, axial spondyloarthritis affects roughly 0.3% to 1.4% of the population, with about 1% prevalence in the United States. Disease onset typically occurs early in life—more than 80% of patients develop symptoms before age 30. Radiographic disease is more common in men, while non-radiographic disease occurs equally in men and women.

A major challenge in this condition is diagnostic delay, which averages nearly seven years from symptom onset. This delay contributes to progressive inflammation, structural damage, and functional impairment before effective therapy is started.

The pathogenesis of axial spondyloarthritis involves a combination of genetic susceptibility, immune dysregulation, and environmental triggers. The strongest genetic risk factor is HLA-B27, present in 80–90% of patients with ankylosing spondylitis.

Several mechanisms have been proposed to explain how HLA-B27 contributes to disease:

• Presentation of arthritogenic peptides to CD8+ T cells • Formation of HLA-B27 dimers, which activate innate immune receptors • Misfolding of HLA-B27 proteins, triggering an unfolded protein response and increased cytokine signaling

At the center of the inflammatory cascade lies the IL-23 / IL-17 axis, which drives activation of Th17 cells and production of pro-inflammatory cytokines including IL-17 and TNF-α. Mechanical stress at the entheses—the sites where ligaments and tendons attach to bone—triggers inflammation, making enthesitis the hallmark pathological process. Chronic inflammation eventually stimulates pathologic new bone formation, producing syndesmophytes and spinal ankylosis.

Clinically, the hallmark symptom is inflammatory back pain, present in more than 80% of patients. Key features include:

• Onset before age 45 years • Gradual onset • Morning stiffness lasting more than 30 minutes • Improvement with exercise • No improvement with rest

Extra-articular manifestations are common and often provide diagnostic clues.

The most frequent is acute anterior uveitis, occurring in 25–30% of patients. Episodes typically present with sudden eye pain, redness, photophobia, and blurred vision.

Other associated conditions include:

• Inflammatory bowel disease (5–10%) • Psoriasis (about 10%) • Cardiovascular involvement, including aortic regurgitation and conduction abnormalities • Pulmonary restriction due to chest wall rigidity

Because early disease may not show radiographic damage, classification relies on modern criteria.

The Modified New York Criteria require definite radiographic sacroiliitis and therefore identify only advanced disease.

In contrast, the ASAS classification criteria for axial spondyloarthritis allow earlier diagnosis. These criteria apply to patients with chronic back pain lasting ≥3 months with onset before age 45 and include two diagnostic pathways:

• Imaging arm: sacroiliitis on MRI or radiograph plus ≥1 SpA feature • Clinical arm: HLA-B27 positivity plus ≥2 SpA features

These criteria have approximately 83% sensitivity and 84% specificity, enabling detection of earlier disease stages.

Monitoring disease activity is critical to guide treatment decisions. The Ankylosing Spondylitis Disease Activity Score (ASDAS) is the preferred measure because it incorporates both patient-reported symptoms and inflammatory markers such as CRP.

ASDAS categories include:

• Inactive disease: <1.3 • Low activity: 1.3–2.1 • High activity: 2.1–3.5 • Very high activity: >3.5

Management begins with non-pharmacologic therapy, which remains foundational for all patients. This includes structured exercise programs, physical therapy, posture training, and smoking cessation, as smoking is associated with worse radiographic progression and poorer treatment response.

First-line pharmacologic therapy is NSAIDs, which reduce pain and inflammation. Continuous therapy may be more effective than intermittent use, although fewer than one quarter of patients achieve complete symptom control with NSAIDs alone.

For patients with persistent disease activity, biologic therapy is the next step.

TNF inhibitors were the first biologics proven effective, producing ASAS20 response rates of roughly 60% and reducing radiographic progression.

More recently, IL-17 inhibitors such as secukinumab and ixekizumab have shown comparable efficacy. A newer agent, bimekizumab, blocks both IL-17A and IL-17F, offering promising results.

JAK inhibitors, including upadacitinib and tofacitinib, provide an oral treatment option and demonstrate response rates exceeding 50%, though regulatory agencies caution about risks including cardiovascular events and infections.

Despite the strong genetic association with IL-23, IL-23 inhibitors have not demonstrated clinical benefit in axial spondyloarthritis, highlighting the complexity of immune signaling pathways.

Long-term outcomes vary widely. The strongest predictor of future structural damage is existing syndesmophytes at baseline. Other poor prognostic factors include male sex, smoking, early hip involvement, and persistent systemic inflammation.

Complications can also arise from the structural rigidity of the spine. Osteoporosis and vertebral fractures occur in up to 10% of patients, meaning new spinal pain—even after minor trauma—should prompt evaluation for fracture.

We close with the key clinical takeaways:

• Axial spondyloarthritis is a spectrum ranging from non-radiographic disease to classic ankylosing spondylitis • Inflammatory back pain beginning before age 45 is the key clinical clue • HLA-B27 and the IL-23/IL-17 inflammatory pathway play central roles in pathogenesis • MRI allows earlier diagnosis before radiographic damage appears • Biologic therapies targeting TNF and IL-17 dramatically improve disease control

Early recognition and treatment are critical—because once structural ankylosis develops, damage is irreversible.

Prosthetic Heart Valve Selection and Clinical Management Guide for the Hospitalist01 Apr 202600:34:57

In this episode of Hospital Medicine Unplugged, we sprint through prosthetic heart valves—how to choose between mechanical and bioprosthetic valves, manage anticoagulation safely, recognize complications, and navigate the expanding role of transcatheter valve replacement.

We begin with the two major categories of prosthetic valves: mechanical valves and bioprosthetic (tissue) valves. Mechanical valves are constructed from durable materials such as pyrolytic carbon and are designed to last decades, but their thrombogenic surface requires lifelong anticoagulation with a vitamin K antagonist.

Anticoagulation targets depend on valve position and risk factors. • Mechanical aortic valve: target INR 2.5 • Mechanical mitral valve or high-risk aortic valve: target INR 3.0

In most patients, low-dose aspirin (75–100 mg daily) is added to vitamin K antagonist therapy to further reduce thromboembolic risk.

Bioprosthetic valves, in contrast, are made from porcine valves or bovine pericardium. These valves are less thrombogenic, which allows for short-term anticoagulation (typically 3–6 months) after implantation followed by lifelong antiplatelet therapy with aspirin. The trade-off is durability—structural valve degeneration (SVD) eventually occurs due to calcification, fibrosis, or leaflet tearing.

Choosing between valve types requires balancing durability versus anticoagulation risk. Mechanical valves generally offer better long-term durability, while bioprosthetic valves avoid lifelong anticoagulation but may require future reoperation.

Age is one of the most important factors in valve selection. Evidence from large observational studies demonstrates that mechanical valves provide survival advantages in younger patients, particularly: • Aortic valve replacement: survival benefit up to about age 55 • Mitral valve replacement: survival benefit up to about age 70

Current ACC/AHA guidelines generally recommend: • Mechanical valves: younger patients (<50 years for aortic position, <65 years for mitral) • Bioprosthetic valves: older patients or those with contraindications to long-term anticoagulation

The treatment landscape has changed dramatically with the development of transcatheter aortic valve replacement (TAVR). Initially reserved for patients with prohibitive surgical risk, TAVR is now widely used across risk groups.

Landmark trials such as PARTNER 3 demonstrated that in low-risk patients with severe aortic stenosis, TAVR produced outcomes comparable to surgical valve replacement at five years. TAVR offers advantages including lower rates of atrial fibrillation and bleeding, though it carries higher risks of paravalvular regurgitation and pacemaker implantation.

Guidelines now recommend: • TAVR as a Class I option for patients who are inoperable or high surgical risk • Either TAVR or surgical replacement for patients aged 65–80 years, depending on anatomy and patient factors

Anticoagulation management remains one of the most critical aspects of prosthetic valve care. Direct oral anticoagulants (DOACs are contraindicated in mechanical valves). The RE-ALIGN trial showed increased thromboembolic and bleeding complications with dabigatran compared with warfarin, leading to early termination of the study. More recently, the PROACT Xa trial evaluating apixaban in patients with On-X mechanical valves also demonstrated excess thromboembolic events.

For bioprosthetic valves, however, DOACs may be used in patients who develop atrial fibrillation, although long-term data remain limited.

Despite technological advances, prosthetic valves carry important complications. One of the most serious is prosthetic valve endocarditis (PVE), which is associated with high mortality. Management requires prolonged intravenous antibiotics, typically for at least six weeks, and surgery may be required for heart failure, uncontrolled infection, or large vegetations.

Another major complication is prosthetic valve thrombosis, particularly with mechanical valves. Management depends on clinical severity and thrombus size. Options include urgent surgery or low-dose, slow-infusion fibrinolysis, with modern thrombolytic protocols achieving over 90% success rates and low complication rates.

A subtler but clinically important issue is prosthesis–patient mismatch (PPM). This occurs when the effective orifice area of the prosthetic valve is too small relative to the patient’s body surface area, creating persistent obstruction despite valve replacement. Severe PPM is defined as indexed effective orifice area <0.65 cm²/m² and is associated with higher mortality, reduced left ventricular mass regression, and worse heart failure outcomes.

Certain populations require special consideration. Pregnancy with mechanical valves carries substantial maternal and fetal risk due to the competing challenges of anticoagulation and thrombosis prevention. Warfarin provides the most reliable valve protection but carries risk of embryopathy at higher doses. For women planning pregnancy, bioprosthetic valves are often preferred, even though they may require earlier replacement.

Finally, structural valve degeneration is the major limitation of bioprosthetic valves. The process occurs gradually and progresses through stages—from early structural changes without hemodynamic impact to severe valve dysfunction requiring reintervention. Risk factors for accelerated degeneration include younger age, renal disease, hypertension, hyperparathyroidism, and prosthesis–patient mismatch.

Because degeneration can occur silently, lifelong surveillance with periodic echocardiography is essential for all patients with prosthetic valves.

We close with the key clinical takeaways:

• Mechanical valves offer durability but require lifelong warfarin therapy • Bioprosthetic valves avoid chronic anticoagulation but eventually degenerate • DOACs are contraindicated in mechanical valves • TAVR has expanded treatment options across all surgical risk groups • Complications include thrombosis, prosthetic valve endocarditis, structural degeneration, and prosthesis–patient mismatch

Prosthetic valve management is a lifelong process—successful outcomes depend not only on the procedure itself but on careful anticoagulation, surveillance, and early recognition of complications.

Asbestosis: Pathogenesis, Clinical Diagnosis, and Management Strategies in the Hospitalized Patient30 Mar 202600:29:31

In this episode of Hospital Medicine Unplugged, we sprint through asbestosis—understand how inhaled fibers trigger progressive pulmonary fibrosis, recognize key radiographic features, and manage patients with attention to malignancy risk and progressive fibrotic disease.

We start with pathophysiology, where the story begins decades before symptoms appear. After inhalation, asbestos fibers deposit in the distal airways and alveoli. Alveolar macrophages attempt to engulf these fibers, but many fibers are too long to be fully internalized—triggering “frustrated phagocytosis.” This leads to persistent macrophage activation and release of inflammatory mediators including TNF-α, IL-1, and TGF-β. At the same time, reactive oxygen species form both from macrophage activation and from iron on the fiber surface, amplifying oxidative injury.

A key early event is alveolar epithelial cell apoptosis, driven by mitochondrial injury, p53-mediated pathways, and endoplasmic reticulum stress. Loss of epithelial integrity and chronic inflammation stimulate fibroblast activation and collagen deposition, ultimately producing the progressive interstitial fibrosis that defines asbestosis.

Not all asbestos fibers carry the same risk. Amphibole fibers—particularly crocidolite and amosite—are far more fibrogenic and carcinogenic than chrysotile fibers. Their needle-like shape, durability, and resistance to biological clearance allow them to persist in lung tissue for decades. Fiber dimensions matter: long fibers (>10–20 μm) and extremely thin fibers (<0.25 μm) pose the highest disease risk because they reach distal lung regions and resist macrophage clearance.

One of the defining features of asbestos disease is extraordinary latency. Clinical asbestosis usually develops 20–40 years after the first exposure, with peak disease occurrence around 40–45 years after exposure begins. Lung cancer tends to occur earlier, typically 30–35 years after exposure. Disease progression varies—some patients remain stable while others develop progressive fibrotic lung disease with significant annual declines in FVC, particularly those with fibrotic patterns on HRCT.

Diagnosis relies on a combination of exposure history, latency, imaging, and pulmonary function testing. According to consensus guidelines, the diagnosis requires:

• Documented asbestos exposure • Appropriate latency interval • Radiographic evidence of interstitial fibrosis • Restrictive lung disease with reduced DLCO

While chest X-ray can detect classic small irregular opacities, high-resolution CT is far more sensitive. Key HRCT findings include:

• Subpleural curvilinear lines (one of the most specific findings) • Intralobular and interlobular septal thickening • Parenchymal bands • Honeycombing in advanced disease

Importantly, most patients with asbestosis also show benign pleural abnormalities, such as pleural plaques or diaphragmatic pleural thickening, which strongly support asbestos exposure.

Unfortunately, no disease-modifying therapies are currently approved specifically for asbestosis. Management traditionally focuses on supportive care, including:

• Smoking cessation • Vaccination against influenza and pneumococcus • Pulmonary rehabilitation • Oxygen therapy for hypoxemia

However, the treatment landscape is evolving. Because asbestosis can behave like other progressive fibrosing interstitial lung diseases, antifibrotic therapies are increasingly considered for patients with progressive disease. Nintedanib, approved for progressive fibrosing ILD, may slow lung function decline in patients with progressive asbestosis. Early studies of pirfenidone suggest acceptable safety and potential benefit, though definitive evidence remains limited.

Another critical dimension of asbestos exposure is malignancy risk. Asbestos causes two to six times more lung cancers than mesotheliomas, making asbestos-related lung cancer a major public health burden. The interaction with smoking is particularly dangerous: asbestos and smoking have a synergistic effect on lung cancer risk. In exposed workers, the combined effect can increase lung cancer mortality more than 30-fold.

Importantly, asbestos exposure increases lung cancer risk even in nonsmokers, but smoking cessation dramatically reduces risk over time. Within 10 years of quitting, lung cancer mortality drops significantly, and after 30 years, risk approaches that of never-smokers.

For malignant mesothelioma, amphibole fibers again carry the greatest risk. Crocidolite exposure has the highest potency, and mesothelioma risk continues to rise 40–50 years after initial exposure.

Because treatment options for mesothelioma remain limited, prevention and early detection are essential. The most effective intervention is elimination of exposure, enforced through occupational safety regulations, air monitoring, and protective equipment.

For individuals with significant asbestos exposure, low-dose CT screening can help detect early lung cancers, improving survival outcomes. Unfortunately, routine screening for mesothelioma is not currently recommended, as effective early detection strategies remain lacking.

We close with the key clinical takeaways:

• Asbestosis results from chronic macrophage activation and epithelial injury triggered by persistent asbestos fibers • Amphibole fibers pose the highest risk due to their durability and biopersistence • Disease latency often exceeds 20–40 years • HRCT is the most sensitive imaging modality for diagnosis • Antifibrotic therapies may benefit patients with progressive fibrotic phenotypes • Smoking cessation dramatically reduces asbestos-related lung cancer risk

Asbestosis remains a preventable occupational disease, but its long latency means clinicians continue to encounter its consequences decades after exposure—making exposure history, imaging recognition, and malignancy surveillance critical in modern clinical practice.

A Comprehensive Clinical Guide to Glomerulonephritis for the Hospitalist27 Mar 202600:35:40

In this episode of Hospital Medicine Unplugged, we sprint through glomerulonephritis—recognize the nephritic syndrome, decode complement patterns and immunofluorescence clues, and manage diseases ranging from self-limited post-infectious GN to rapidly progressive crescentic disease.

We start with the clinical syndrome of glomerulonephritis, defined by glomerular inflammation producing hematuria, hypertension, edema, and reduced kidney function. The classic picture is nephritic syndrome—tea- or cola-colored urine, oliguria, periorbital edema, and elevated blood pressure. At the microscopic level, RBC casts are the pathognomonic finding, proving that bleeding originates from the glomerulus rather than the urinary tract.

Understanding disease requires revisiting the glomerular filtration barrier, composed of three layers: fenestrated endothelium, the glomerular basement membrane (GBM), and podocytes connected by slit diaphragms. This barrier normally filters plasma while retaining proteins. Podocytes are terminally differentiated and poorly regenerative, making them particularly vulnerable to immune-mediated injury.

The core pathophysiology of GN is immune-mediated inflammation. Antibodies, immune complexes, and complement activation trigger inflammatory cascades within the glomerulus. This leads to endocapillary proliferation, mesangial expansion, and leukocyte infiltration, narrowing capillary lumens and lowering GFR. Capillary wall damage allows red blood cells to leak into urine, while the sudden decline in filtration drives sodium and water retention, producing hypertension and edema.

Modern classification emphasizes pathogenesis rather than morphology, and most GN falls into five categories:

• Immune-complex GN – granular immunoglobulin deposition (post-infectious GN, IgA nephropathy, lupus nephritis, MPGN) • Pauci-immune GN – minimal immune deposition, typically ANCA-associated vasculitis • Anti-GBM disease – linear IgG staining along the basement membrane • Monoclonal immunoglobulin GN – related to plasma cell disorders • C3 glomerulopathy – dominant complement deposition from alternative pathway dysregulation

Epidemiology varies by disease. Post-streptococcal GN primarily affects children aged 2–10 years, particularly in developing regions. In contrast, IgA nephropathy is the most common primary glomerular disease worldwide and typically presents in young adults. Interestingly, epidemiology has shifted: childhood PSGN is declining, while adult infection-related GN—often associated with staphylococcal infections—is increasing.

Clinical presentation depends on the underlying disease. Post-streptococcal GN typically occurs 1–12 weeks after a streptococcal infection, producing abrupt edema, hypertension, and hematuria. IgA nephropathy, in contrast, often presents with synpharyngitic hematuria—visible hematuria occurring simultaneously with an upper respiratory infection.

The urinalysis is the diagnostic cornerstone. Key findings include dysmorphic red blood cells, RBC casts, and mild-to-moderate proteinuria. Complement levels help narrow the differential:

• Low C3 and low C4: lupus nephritis, cryoglobulinemia, immune-complex MPGN • Low C3 with normal C4: post-infectious GN or C3 glomerulopathy • Normal complement: IgA nephropathy, ANCA-associated GN, anti-GBM disease

A crucial teaching point: C3 should normalize within 6–8 weeks in post-streptococcal GN. Persistent hypocomplementemia suggests another diagnosis, such as lupus nephritis or MPGN.

Additional testing includes ASO titers and anti-DNase B antibodies for streptococcal infection, autoimmune markers such as ANA and ANCA, and viral testing for hepatitis B, hepatitis C, and HIV.

Imaging plays a limited role. Renal ultrasound typically shows normal or enlarged kidneys in acute GN, helping distinguish acute inflammatory disease from chronic kidney disease.

When the diagnosis remains unclear—or when disease is severe—a kidney biopsy is essential. Histology reveals characteristic patterns:

• Post-infectious GN: diffuse endocapillary proliferation with neutrophils • Crescents: severe injury indicating rapidly progressive GN • Electron microscopy: classic subepithelial “hump-shaped” deposits in post-infectious disease

Immunofluorescence patterns guide classification:

• Granular deposition: immune-complex GN • Linear IgG: anti-GBM disease • Pauci-immune: ANCA vasculitis • C3-dominant: C3 glomerulopathy

Management begins with supportive care for all patients. Key interventions include:

• Blood pressure control, ideally ≤120/70 mmHg with ACE inhibitors or ARBs • Sodium restriction (<2 g/day) • Diuretics for volume overload • Fluid restriction when necessary

Treatment then becomes etiology-specific.

For post-infectious GN, therapy is largely supportive because the disease usually resolves spontaneously. Edema typically improves within 1–2 weeks, and renal function normalizes within about 4 weeks.

IgA nephropathy, however, may progress. Treatment strategies now include:

• Targeted-release budesonide to reduce intestinal IgA production • SGLT2 inhibitors for kidney protection • Sparsentan, a dual endothelin–angiotensin receptor antagonist • Iptacopan, a complement pathway inhibitor

In rapidly progressive (crescentic) GN, immediate therapy is essential. Treatment typically includes:

• High-dose glucocorticoids (IV methylprednisolone followed by oral prednisone) • Cyclophosphamide or rituximab • Plasma exchange for anti-GBM disease

For ANCA-associated vasculitis, rituximab is now equivalent to cyclophosphamide for induction therapy and may be superior in relapsing disease.

Prognosis varies widely. Post-streptococcal GN in children generally resolves completely, though subtle long-term kidney risk may remain. IgA nephropathy has a much more variable course, with up to half of patients progressing to kidney failure within 10 years.

Predictors of poor outcome include:

• Persistent hypertension • Proteinuria >1 g/day • Reduced eGFR at diagnosis • Extensive fibrosis or crescents on biopsy

We close with the high-yield clinical pearls:

• RBC casts confirm glomerular bleeding • Complement patterns dramatically narrow the differential diagnosis • Synpharyngitic hematuria points to IgA nephropathy • Crescents signal severe rapidly progressive disease • Persistently low C3 beyond 8 weeks argues against post-streptococcal GN

Glomerulonephritis is not a single disease but a spectrum of immune-mediated kidney disorders—and successful management depends on integrating clinical presentation, serology, complement levels, and biopsy findings to identify the exact mechanism driving glomerular injury.

Modern Clinical Management of Thyroid Carcinoma and the Hospitalist's Role in Coordination25 Mar 202600:29:28

In this episode of Hospital Medicine Unplugged, we sprint through thyroid cancer—understand the epidemiologic paradox of rising incidence but stable mortality, stage disease using modern AJCC criteria, apply ATA recurrence risk stratification, and tailor therapy from surgery and radioiodine to targeted molecular treatments.

We start with the epidemiology of thyroid carcinoma, the most common endocrine malignancy and the ninth most common cancer worldwide. In 2022 alone, there were roughly 821,000 new cases and 47,500 deaths globally. The disease shows a strong female predominance—about three quarters of cases occur in women, and the median age at diagnosis is in the early 50s. Notably, thyroid cancer is also the most common malignancy among adolescents and young adults aged 16–33 years.

One of the most striking trends is the dramatic rise in incidence over the past four decades. Global age-standardized incidence increased substantially from about 2.1 per 100,000 in 1990 to over 3.1 per 100,000 in 2017, with extremely high rates reported in countries such as South Korea, Cyprus, Ecuador, China, and Turkey. Yet mortality has remained remarkably stable at roughly 0.5 per 100,000, suggesting that much of the increase reflects overdiagnosis rather than a true surge in aggressive disease.

The driver behind this phenomenon is increased detection of small papillary thyroid cancers, often discovered incidentally during thyroid ultrasonography or cross-sectional imaging. Some studies estimate that more than 75% of thyroid cancers globally may represent overdiagnosis, particularly in high-income countries where imaging is widespread. Encouragingly, incidence rates have begun to plateau or decline in some regions following guideline changes discouraging unnecessary biopsy and treatment of very small nodules.

Next, we turn to staging, which guides prognosis and management. The AJCC 8th edition TNM staging system introduced an important shift by raising the prognostic age cutoff from 45 to 55 years. This reflects the excellent survival outcomes seen in younger patients.

For patients younger than 55 years, staging is remarkably simple: • Stage I: any tumor size, any lymph node status, no distant metastasis • Stage II: distant metastasis present

This simplified system reflects the outstanding prognosis in younger individuals, with more than 98% survival regardless of tumor characteristics.

For patients 55 years and older, staging becomes more detailed and incorporates tumor size, lymph node involvement, and extrathyroidal extension. Importantly, the 8th edition refined the definition of extrathyroidal extension so that only gross invasion of strap muscles qualifies for T3b staging, which has downstaged many patients and improved prognostic accuracy.

However, staging alone does not fully predict recurrence. That role belongs to the American Thyroid Association (ATA) risk stratification system, which categorizes patients as low, intermediate, or high risk of recurrence.

Approximate recurrence rates are: • Low risk: ~1.5% • Intermediate risk: ~5% overall • High risk: ~25%

A key innovation in ATA management is dynamic risk stratification, where risk is continuously updated based on response to therapy.

Response categories include: • Excellent response: ~4.7% recurrence risk • Indeterminate response: ~17% recurrence • Biochemically incomplete: ~58% recurrence • Structurally incomplete: ~84% recurrence

This dynamic approach allows clinicians to de-escalate surveillance and treatment for patients who demonstrate excellent responses over time.

At the molecular level, thyroid cancer has a remarkably simple genomic landscape, dominated by mutations activating the MAPK signaling pathway.

The most common driver mutation is BRAF V600E, found in about 60% of papillary thyroid cancers. This mutation is associated with classic and tall-cell variants, increased lymph node metastases, and reduced responsiveness to radioactive iodine due to suppression of the sodium-iodide symporter.

Another important group includes RAS mutations, seen in follicular thyroid cancers and follicular-variant papillary carcinomas. These tumors often demonstrate vascular invasion but retain better responsiveness to radioactive iodine therapy.

Chromosomal rearrangements also play a role. RET/PTC fusions are common in radiation-induced thyroid cancers and pediatric cases, while TERT promoter mutations—particularly when combined with BRAF mutations—are associated with aggressive disease and poor prognosis.

Management of differentiated thyroid cancer increasingly emphasizes risk-adapted therapy, particularly regarding radioactive iodine (RAI).

RAI can serve three purposes: • Remnant ablation after surgery • Adjuvant therapy to reduce recurrence risk • Treatment of known metastatic disease

Modern guidelines recommend avoiding routine RAI in low-risk patients, particularly those with small intrathyroidal papillary cancers ≤2 cm, negative lymph nodes, low postoperative thyroglobulin, and normal ultrasound.

RAI becomes selectively recommended when additional risk factors are present, such as tumors >4 cm, nodal metastases, lymphatic invasion, aggressive histologic variants, or elevated postoperative thyroglobulin levels.

For high-risk disease, including gross extrathyroidal extension, extensive nodal disease, or distant metastases, RAI therapy remains standard because it improves both survival and recurrence outcomes.

When thyroid cancer becomes radioiodine-refractory, systemic therapy may be required. Several targeted agents are now available.

First-line multikinase inhibitors include: • Lenvatinib, which significantly improves progression-free survival and has response rates approaching 65% • Sorafenib, with more modest response rates but proven efficacy

Second-line therapy includes cabozantinib for patients progressing after first-line agents.

Precision medicine is increasingly important. Tumors with specific driver mutations may respond dramatically to targeted therapies:

• RET fusions: treated with selpercatinib or pralsetinib, with response rates approaching 80–90% • BRAF V600E: targeted with dabrafenib plus trametinib, particularly in anaplastic thyroid cancer • NTRK fusions: treated with larotrectinib or entrectinib, with high response rates

Despite these advances, systemic therapy is not curative and often causes substantial side effects. Therefore, treatment should generally be reserved for progressive or symptomatic disease, while patients with slow-growing, asymptomatic metastases may be safely observed.

We close with the key clinical takeaways:

• Rising thyroid cancer incidence largely reflects overdiagnosis of small papillary tumors • AJCC staging predicts survival, while ATA risk stratification predicts recurrence • Dynamic response-to-therapy assessment allows individualized long-term management • Molecular drivers like BRAF, RAS, and RET shape prognosis and treatment options • Radioactive iodine is increasingly used selectively rather than routinely

Thyroid cancer illustrates a modern shift in oncology—from one-size-fits-all treatment toward precision risk-adapted care, balancing effective therapy with avoidance of unnecessary intervention.

Anaphylaxis: Mechanisms, Triggers, and Clinical Management in the Hospitalized Patient23 Mar 202600:29:49

In this episode of Hospital Medicine Unplugged, we sprint through anaphylaxis—recognize the rapid systemic reaction, understand the mast-cell storm driving shock, and deliver epinephrine immediately to prevent cardiovascular collapse.

We begin with the definition and diagnostic framework. Anaphylaxis is a severe, rapid-onset, life-threatening systemic hypersensitivity reaction. When it progresses to circulatory collapse with profound vasodilation and vascular leak, it becomes anaphylactic shock, a form of distributive shock with relative hypovolemia. Modern guidelines define anaphylaxis clinically: acute onset of illness with skin or mucosal symptoms plus respiratory compromise, hypotension, or severe gastrointestinal symptoms, or hypotension/bronchospasm after known allergen exposure—even without skin findings.

Next comes epidemiology. Anaphylaxis occurs in roughly 50–112 episodes per 100,000 person-years, and 1.6–5.1% of adults in the United States experience an episode during their lifetime. Fortunately, modern treatment has kept mortality low. Case fatality rates among emergency presentations are about 0.25–0.33%, translating to roughly 186–225 deaths per year in the United States.

Triggers vary by age. Food-induced anaphylaxis predominates in young children, while medication-induced reactions are more common in adults, especially those over age 50.

At the core of anaphylaxis lies mast-cell and basophil activation. In classic IgE-mediated type I hypersensitivity, an allergen first sensitizes the immune system, leading B cells to produce IgE antibodies that bind to high-affinity FcεRI receptors on mast cells and basophils. On re-exposure, allergen cross-linking of IgE triggers rapid cellular degranulation.

This releases a cascade of mediators including:

• Histamine and tryptase • Leukotrienes and prostaglandins • Platelet-activating factor (PAF) • Cytokines such as IL-4 and IL-6

These mediators cause vasodilation, endothelial barrier disruption, bronchoconstriction, and massive capillary leak, shifting fluid from the intravascular space to tissues. The result is hypotension, airway compromise, and multisystem dysfunction.

Not all anaphylaxis is IgE mediated. Alternative mechanisms include IgG-mediated reactions, complement activation, contact system activation, and direct mast-cell activation via MRGPRX2 receptors. Clinically, these non-IgE pathways can produce identical presentations, which is why anaphylaxis remains a clinical diagnosis rather than a laboratory one.

The most common triggers fall into three major groups:

• Foods (≈32–37%) • Medications (≈21–58%) • Insect venom (≈15–25%)

In the United States, nine foods account for over 90% of IgE-mediated food allergies: milk, egg, wheat, soy, peanuts, tree nuts, fish, shellfish, and sesame. Peanuts remain the leading cause of fatal food-related anaphylaxis.

An emerging cause is alpha-gal syndrome, a delayed meat allergy triggered by tick bites, affecting tens to hundreds of thousands of individuals in the United States.

Medications are the most common trigger in adults, particularly beta-lactam antibiotics, followed by NSAIDs, biologic agents, chemotherapy drugs, and ACE inhibitors.

Another important concept is cofactors—conditions that lower the threshold for anaphylaxis. These include exercise, alcohol, infection, menstruation, and NSAID use. A classic example is food-dependent exercise-induced anaphylaxis, where patients tolerate a food normally but develop anaphylaxis if they exercise soon after ingestion.

Diagnosis relies on clinical criteria, most commonly the NIAID/FAAN criteria. Anaphylaxis is highly likely when there is acute involvement of skin or mucosa plus respiratory compromise or hypotension, multisystem involvement after allergen exposure, or isolated hypotension after exposure to a known trigger.

Laboratory confirmation is not required in the acute setting, but serum tryptase measured 90 minutes to 4 hours after symptom onset can support the diagnosis. An increase of 1.2 × baseline plus 2 ng/mL strongly suggests mast-cell activation.

Now to the most critical step: treatment.

Epinephrine is the first-line and life-saving therapy.

It should be administered immediately intramuscularly into the mid-anterolateral thigh at a dose of:

• 0.01 mg/kg of 1 mg/mL solution • Maximum 0.3 mg in children • Maximum 0.5 mg in adults

Doses can be repeated every 5–15 minutes if symptoms persist. There are no contraindications to epinephrine in anaphylaxis—even in patients with cardiovascular disease.

Delayed epinephrine administration is the strongest modifiable risk factor for fatal anaphylaxis.

Adjunctive therapies follow epinephrine but never replace it. These include:

• High-flow oxygen • Aggressive IV crystalloid resuscitation • H1 antihistamines (diphenhydramine) • H2 blockers • Systemic corticosteroids • Bronchodilators for bronchospasm

For patients taking beta-blockers who develop refractory hypotension, glucagon may be used because it increases cyclic AMP independent of beta receptors.

Rarely, patients develop refractory anaphylactic shock, defined by persistent symptoms despite multiple epinephrine doses. Management may require IV epinephrine infusion, additional vasopressors, airway management, and aggressive fluid resuscitation. In extreme cases, methylene blue or extracorporeal life support has been used as rescue therapy.

Another important phenomenon is biphasic anaphylaxis, where symptoms recur after initial resolution without new allergen exposure. This occurs in about 5–6% of cases, typically within 10 hours.

Recommended observation periods depend on severity:

• Minimum 4 hours for uncomplicated reactions • 6–8 hours with respiratory compromise • 12–24 hours for hypotension or severe reactions

Longer monitoring is advised for patients with severe initial presentation, multiple epinephrine doses, asthma, unknown trigger, or prior biphasic reactions.

Special consideration is needed for patients on beta-blockers or ACE inhibitors, which may increase severity of reactions and blunt compensatory cardiovascular responses. These medications are not absolutely contraindicated, but management should involve shared decision-making regarding risks and benefits.

Long-term management focuses on prevention and preparedness.

All patients who experience anaphylaxis should receive:

• Epinephrine autoinjectors • Education on prompt use • Referral for allergy evaluation and trigger identification

Patients should carry two autoinjectors at all times, as repeat dosing may be required.

Additional prevention strategies include allergen avoidance, personalized emergency action plans, medical alert identification, and immunotherapy when appropriate. For example, venom immunotherapy is highly effective for Hymenoptera sting allergy, and oral immunotherapy is now available for peanut allergy.

We close with the key clinical pearls:

• Anaphylaxis is a clinical diagnosis—do not delay treatment • Epinephrine IM is the first and most important therapy • Food, medications, and insect venom are the most common triggers • Cofactors like exercise or alcohol can lower reaction thresholds • Always prescribe epinephrine autoinjectors and educate patients before discharge

Recognize the signs, inject epinephrine early, and monitor carefully—because in anaphylaxis, minutes matter and rapid treatment saves lives.

Upper Motor Neuron Syndrome: Pathophysiology and Clinical Management in the Hospitalized Patient20 Mar 202600:27:47

In this episode of Hospital Medicine Unplugged, we sprint through upper motor neuron (UMN) syndromes—how spasticity develops, how to separate true reflex hyperexcitability from fixed stiffness, and how to diagnose and manage major UMN diseases like PLS and hereditary spastic paraplegia.

We begin with spasticity, a defining feature of UMN injury that is not simply an immediate “release phenomenon.” Its delayed appearance after stroke or spinal cord injury points to maladaptive plasticity in both the spinal cord and brain. The core problem is loss of descending inhibitory control, with reduced corticospinal input, increased reticulospinal drive, impaired spinal inhibitory circuits, heightened alpha motor neuron excitability, and reduced postactivation depression, especially with immobilization.

Clinically, spasticity is a velocity-dependent increase in tone caused by hyperexcitable stretch reflexes. But bedside hypertonia often has two components: reflex-mediated spasticity and intrinsic soft tissue stiffness from contracture and rheologic muscle change. That distinction matters. The Modified Ashworth Scale measures overall resistance, but the Tardieu Scale better separates dynamic spasticity from fixed mechanical tightness.

We then turn to primary lateral sclerosis (PLS), the prototypical adult UMN-predominant degenerative disorder. The 2020 consensus criteria define probable PLS as 2–4 years of progressive UMN syndrome and definite PLS as more than 4 years of symptoms. That time threshold matters because shorter duration carries higher risk of later ALS conversion. Even in clinically pure PLS, minor EMG abnormalities like fasciculations or fibrillations can occur, especially with longer disease duration.

Next is hereditary spastic paraplegia (HSP), a genetically diverse disorder marked by bilateral leg spasticity, hyperreflexia, and extensor plantar responses from length-dependent corticospinal tract degeneration. HSP is classified into pure forms, where spastic paraparesis dominates, and complex forms, where additional neurologic features appear. Although SPAST (SPG4) and SPG7 are among the most common mutations, a genetic diagnosis is still achieved in only a minority of patients.

MRI is the gold standard imaging study in suspected UMN disease. Key findings include corticospinal tract T2/FLAIR hyperintensity, especially in the posterior limb of the internal capsule and cerebral peduncles, as well as the “motor band sign,” a T2/SWI hypointensity in the precentral gyrus reflecting iron deposition. Motor cortex atrophy may be even more sensitive than the physical exam for detecting UMN degeneration and can appear before overt clinical signs.

We also highlight the distinction between pseudobulbar palsy and bulbar palsy. Pseudobulbar palsy comes from bilateral corticobulbar UMN lesions and produces spastic dysarthria, brisk jaw jerk, and exaggerated gag reflex. It is often accompanied by pseudobulbar affect—uncontrollable laughing or crying out of proportion to context. In contrast, bulbar palsy reflects LMN dysfunction of cranial nerve nuclei or nerves.

Management of spasticity follows a stepwise approach. Start with physical therapy, stretching, splinting, bracing, and positioning. For focal spasticity, botulinum toxin A has the strongest evidence and is preferred because it improves tone without systemic sedation. For generalized spasticity, oral agents include baclofen, tizanidine, benzodiazepines, and dantrolene, though benefit is often limited by sedation or weakness. In severe refractory cases, intrathecal baclofen pumps provide greater efficacy at lower doses—but pump failure can cause life-threatening withdrawal.

We close with the take-home moves: recognize that spasticity is dynamic neurophysiology plus biomechanics, use MRI and timeline to refine the diagnosis, distinguish pseudobulbar from bulbar syndromes, and treat spasticity with a layered rehab-first strategy before escalating to botulinum toxin or intrathecal therapy.

UMN syndromes are about more than “increased tone”—they are disorders of descending control, adaptive failure, and progressive disability, and careful phenotyping is what turns bedside findings into precise diagnosis and treatment.

Endovascular Infections: Vascular Grafts, CIEDs, Mycotic Aneurysms & Lemierre Syndrome18 Mar 202601:02:18

In this episode of Hospital Medicine Unplugged, we break down endovascular infections—vascular graft infections, mycotic aneurysms, CIED infections, and septic thrombophlebitis syndromes—focusing on modern epidemiology, evolving microbiology, advanced imaging, and high-yield management strategies.

We begin with epidemiology clinicians should know. Vascular graft infections occur in ~0.5–6% of vascular reconstructions, while endovascular device infections occur in ~0.2–5% of procedures, with TEVAR carrying higher infection risk than abdominal repairs. Meanwhile, cardiac implantable electronic device (CIED) infections have increased substantially, reflecting growing device use.

Next we review key microbiology. Gram-positive cocci cause most vascular graft infections, with coagulase-negative staphylococci now more common than S. aureus. MRSA is increasingly prevalent and linked to worse outcomes, while Pseudomonas aeruginosa leads among gram-negative pathogens. For mycotic aneurysms, Salmonella species remain classic causes, with rare pathogens including Listeria and Mycobacterium tuberculosis.

We then highlight important clinical syndromes. Lemierre syndrome presents with pharyngitis, internal jugular vein thrombosis, and septic emboli (often pulmonary) and is classically caused by Fusobacterium necrophorum, though MRSA and polymicrobial infections are increasingly recognized. Pylephlebitis, sometimes called the abdominal variant of Lemierre syndrome, involves septic thrombosis of the portal venous system.

Diagnosis relies heavily on advanced imaging. CTA is typically the first-line test, while 18F-FDG PET/CT provides high sensitivity (~94%) and excellent negative predictive value, especially in late graft infections. TEE remains essential for suspected CIED infection, though repeat imaging may be needed if initial studies are negative.

Management requires combined antimicrobial and procedural strategies. • ≥6 weeks of antibiotics for most vascular graft infections • Device removal for confirmed CIED infection, with early extraction improving survival • 3–6 weeks of antibiotics for Lemierre syndrome, often metronidazole plus a β-lactam, with MRSA coverage in high-risk patients • Lifelong suppressive therapy may be needed when infected devices cannot be removed

We close with key controversies and outcomes. Anticoagulation for septic thrombophlebitis remains debated, though many experts consider 6–12 weeks of therapy in selected patients. Despite advances, vascular graft infections and mycotic aneurysms carry high mortality—often exceeding 30% at one year—especially with MRSA.

Early recognition, PET/CT-guided diagnosis, aggressive antibiotics, and timely device removal remain the pillars of care for these complex infections.

Clinical Pathophysiology and Evidence-Based Management of Delirium Tremens in the Hospitalized Patient16 Mar 202600:32:59

In this episode of Hospital Medicine Unplugged, we sprint through delirium tremens—the most dangerous stage of alcohol withdrawal—recognize the neurochemical storm, identify high-risk patients, and treat aggressively with benzodiazepines and supportive care to prevent fatal complications.

We begin with epidemiology and why DTs matter. Delirium tremens occurs in 3–5% of hospitalized patients with alcohol withdrawal and represents the most severe manifestation of the withdrawal spectrum. The syndrome combines acute delirium—rapidly fluctuating attention and cognition—with severe autonomic hyperactivity. Historically mortality approached 15%, but with modern aggressive treatment it has fallen to about 1–4%. When death occurs, it is usually due to hyperthermia, malignant arrhythmias, withdrawal seizures, or underlying medical illness.

Next comes the neurobiology driving withdrawal. Chronic alcohol exposure forces the brain to compensate for alcohol’s depressant effects. Over time:

• NMDA glutamate receptors are upregulated • GABA-A inhibitory receptors are downregulated

While alcohol is present, its GABA-enhancing and NMDA-suppressing effects maintain balance. When alcohol is abruptly stopped, that balance collapses. The result is unopposed excitatory neurotransmission, increased glutamate signaling, reduced GABA inhibition, and massive central nervous system hyperexcitability. Additional contributors include increased norepinephrine activity, dopaminergic alterations, and calcium-mediated excitotoxicity, producing the agitation, tremor, and seizure risk characteristic of severe withdrawal.

Risk stratification is essential because not every patient with withdrawal develops delirium tremens. The strongest predictor is a prior history of DTs, which carries a likelihood ratio of roughly 2.9 for recurrence. Other important risk factors include:

• Recent withdrawal seizures, especially multiple seizures • High CIWA-Ar scores (>15) with tachycardia or hypertension • Older age (≥55 years) • Concurrent illness such as infection, trauma, electrolyte abnormalities, or liver disease • Hypokalemia and metabolic derangements

Another key concept is the kindling effect. Repeated withdrawal episodes progressively sensitize neuronal circuits, meaning each withdrawal episode tends to become more severe than the last.

The timeline of alcohol withdrawal follows a predictable pattern.

• 6–12 hours: early withdrawal—tremor, anxiety, tachycardia • 12–24 hours: alcoholic hallucinosis (visual or auditory hallucinations) • 12–48 hours: withdrawal seizures • 72–96 hours: onset of delirium tremens, typically lasting 2–3 days but up to a week

Importantly, about one-third of untreated withdrawal seizures progress to delirium tremens, making early treatment critical.

Clinically, DTs presents with severe agitation and delirium combined with autonomic instability. Key features include:

• Fluctuating confusion and disorientation • Marked agitation and psychomotor hyperactivity • Tachycardia, hypertension, fever, and diaphoresis • Coarse tremor and hyperreflexia • Vivid visual hallucinations, often insects or animals

Diagnosis is clinical—delirium occurring in the context of alcohol withdrawal. The CIWA-Ar scale helps quantify withdrawal severity, but it becomes less reliable once patients develop delirium because it depends on patient responses. In ICU settings, clinicians often switch to CAM-ICU, RASS, MINDS, or DDS scales.

Laboratory evaluation should focus on complications and reversible triggers. Important tests include:

• Electrolytes (magnesium, potassium, phosphate) • Glucose • Liver function tests • Creatine kinase for rhabdomyolysis risk

Neuroimaging should be obtained if the presentation is atypical or focal neurologic deficits are present.

Management centers on rapid sedation and physiologic stabilization.

Benzodiazepines are first-line therapy, acting as GABA-A agonists to counter the hyperexcitable brain. Two dosing strategies dominate:

• Symptom-triggered therapy, which reduces medication exposure and treatment duration • Front-loading with high doses for severe withdrawal (CIWA-Ar ≥19)

Clinicians should not fear very high benzodiazepine doses. Severe DTs may require hundreds of milligrams of diazepam per day, and case reports describe successful treatment with 260–480 mg/day.

Agent selection depends on clinical context:

• Diazepam or chlordiazepoxide – preferred long-acting agents for front-loading • Lorazepam – preferred in liver disease, since it lacks active metabolites

For benzodiazepine-refractory DTs, ICU-level therapies may be required.

Adjunctive options include:

• Phenobarbital, which enhances GABA signaling and may reduce mechanical ventilation risk • Propofol, used in intubated patients with refractory agitation • Dexmedetomidine, an α2-agonist that suppresses sympathetic overactivity while allowing arousable sedation

Antipsychotics should never be used as monotherapy, as they lower seizure threshold. They may be used only as adjuncts for severe hallucinations or agitation.

Supportive care is equally critical. One rule must never be forgotten:

Thiamine must be administered before glucose.

High-dose thiamine—500 mg IV once or twice daily for several days—prevents Wernicke encephalopathy, a devastating but preventable neurologic complication.

Other essential measures include:

• IV fluids and hydration • Aggressive correction of magnesium, potassium, and phosphate • Temperature control and frequent vital monitoring • Calm, well-lit environment with reassurance and reorientation

Patients should be admitted to the ICU when they develop delirium tremens, severe withdrawal (CIWA ≥20), refractory symptoms despite benzodiazepines, unstable vital signs, or serious comorbid illness such as pancreatitis or GI bleeding.

Complications of DTs can be dramatic and life-threatening. They include:

• Cardiac arrhythmias and myocardial ischemia • Hyperthermia • Withdrawal seizures and status epilepticus • Aspiration pneumonia • Rhabdomyolysis with acute kidney injury • Severe electrolyte disturbances, especially hypokalemia

Despite modern treatment, patients who experience DTs have significantly increased long-term mortality, with an annual mortality rate around 8%, particularly due to trauma, suicide, and other alcohol-related causes.

We close with the essential clinical pearls:

• Delirium tremens is a clinical diagnosis—treat immediately • Prior DTs strongly predict recurrence • Withdrawal severity increases with repeated episodes due to kindling • Benzodiazepines are the cornerstone—very high doses may be required • Thiamine must be given before glucose • Always search for concurrent illness such as infection, trauma, or electrolyte abnormalities

Recognize the timeline, treat early, and sedate aggressively—because in delirium tremens, rapid intervention transforms a historically lethal syndrome into a manageable medical emergency.

Evidence-Based Advances in Chronic Spontaneous Urticaria Management in the Hospitalized Patient13 Mar 202600:29:37

In this episode of Hospital Medicine Unplugged, we sprint through urticaria—recognize the wheal, distinguish acute from chronic disease, uncover autoimmune drivers, and step through a modern treatment ladder that now includes biologics and BTK inhibitors.

We start with the definition and epidemiology. Urticaria is characterized by transient pruritic wheals, angioedema, or both, typically resolving within 24 hours without scarring. While about 20% of people experience urticaria at some point in life, chronic spontaneous urticaria (CSU) affects roughly 1% of the population and disproportionately affects women aged 30–50.

The key classification hinges on duration. • Acute urticaria: symptoms lasting <6 weeks • Chronic urticaria: symptoms ≥6 weeks

Fortunately, progression from acute to chronic disease occurs in fewer than 8% of cases. Risk factors for chronicity include antithyroid antibodies and poor response to antihistamines.

Next comes an important shift in our understanding of etiology. Historically, chronic urticaria was labeled “idiopathic” in most cases. We now know that more than half of patients actually have autoimmune disease mechanisms.

Two major autoimmune endotypes exist:

Type I autoimmune (autoallergic) CSU • IgE autoantibodies against autoantigens such as thyroid peroxidase or IL-24 • Leads to mast-cell activation similar to allergic disease

Type IIb autoimmune CSU • IgG autoantibodies against IgE or the FcεRI receptor • Identified in about 8–10% of patients using strict diagnostic criteria

These immune mechanisms explain why less than 35% of CSU cases truly lack detectable autoantibodies.

Diagnosis is largely clinical but follows the “7C” framework: Confirm diagnosis, identify causes, assess cofactors, evaluate comorbidities, assess consequences, evaluate biomarkers, and monitor disease course.

Routine laboratory testing should remain minimal unless clinical clues suggest otherwise. Recommended baseline tests include: • CBC with differential • ESR or CRP • TSH

Certain red flags should trigger referral or further evaluation: • Wheals lasting >24 hours • Residual hyperpigmentation after lesions resolve • Angioedema lasting several days without hives • Systemic symptoms such as fever, arthralgia, or abdominal pain

To measure disease activity, clinicians rely on validated tools.

The Urticaria Activity Score over 7 days (UAS7) is the gold standard. Patients record itch severity and hive count twice daily, producing a score from 0 to 42.

Interpretation: • 0: urticaria-free • 1–6: well controlled • 7–15: mild • 16–27: moderate • 28–42: severe

The Urticaria Control Test (UCT) is another practical tool. A score ≥12 indicates good control, while <12 suggests poorly controlled disease.

Management follows a stepwise escalation strategy.

Step 1: Second-generation H1 antihistamines Agents include cetirizine, loratadine, fexofenadine, levocetirizine, and desloratadine, taken daily rather than as needed. About 40% of patients achieve meaningful symptom reduction with standard dosing.

Step 2: Dose escalation If symptoms persist, antihistamine doses can be increased up to fourfold. Evidence suggests quadrupling the dose of a single antihistamine is more effective than combining multiple agents.

Step 3: Omalizumab For antihistamine-refractory disease, omalizumab 300 mg every 4 weeks is the standard biologic therapy. Clinical trials show complete remission (UAS7 = 0) in about 36% of patients, with substantially higher response rates in real-world practice.

Patients with incomplete response may require higher doses or shorter dosing intervals.

Step 4: Cyclosporine For patients who fail omalizumab, cyclosporine (3–5 mg/kg/day) can improve symptoms in more than half of cases, although monitoring for renal toxicity and hypertension is essential.

Short courses of systemic corticosteroids (20–50 mg/day for <10 days) may help during severe flares but should never be used long-term.

The treatment landscape is expanding rapidly.

Two newly approved therapies include:

Dupilumab An IL-4 receptor α antagonist approved in 2025 for patients ≥12 years with persistent CSU despite antihistamines. Clinical trials showed complete response in about 31% of patients.

Remibrutinib A Bruton tyrosine kinase (BTK) inhibitor approved in 2025 that targets mast-cell signaling downstream of FcεRI activation. Trials demonstrated complete response rates up to ~42% with rapid onset within 2 weeks.

Another critical diagnostic consideration is urticarial vasculitis, which can mimic CSU but requires a different approach.

Key distinguishing features include: • Lesions lasting >24 hours • Pain or burning rather than itching • Residual hyperpigmentation after resolution

Systemic symptoms such as fever, arthralgia, or eye inflammation further increase suspicion. Diagnosis is confirmed by skin biopsy showing leukocytoclastic vasculitis.

Finally, we talk prognosis. Chronic spontaneous urticaria is often self-limited but unpredictable.

Remission rates: • 17% at 1 year • 45% at 5 years • 73% at 20 years

Average disease duration is 1–4 years, though relapse occurs in up to one-third of patients.

We close with the key clinical pearls:

• Chronic urticaria is rarely allergic—most cases involve autoimmune mast-cell activation • High-dose antihistamines (up to four times standard dosing) are guideline-recommended and safe • Omalizumab remains the cornerstone biologic therapy • Cyclosporine, dupilumab, and BTK inhibitors expand options for refractory disease • Always consider urticarial vasculitis when lesions last longer than 24 hours

Recognize the pattern, escalate therapy systematically, and remember—modern immunologic therapies are transforming outcomes for patients with chronic urticaria.

Managing Acute Exacerbations in Fibrotic Interstitial Lung Disease in the Hospitalized Patient11 Mar 202600:45:14

In this episode of Hospital Medicine Unplugged, we sprint through acute exacerbation of interstitial lung disease (AE-ILD)—recognize the sudden decline, rule out infection and cardiac causes, support oxygenation, and navigate a disease with limited treatment options and high mortality.

We begin with the diagnostic framework defined by the 2016 International Working Group. Acute exacerbation is characterized by rapid respiratory deterioration within about 1 month, accompanied by new bilateral ground-glass opacities or consolidation on CT superimposed on pre-existing fibrotic lung disease, with no evidence of cardiac failure or fluid overload. Importantly, this definition now applies across fibrosing interstitial lung diseases, not just idiopathic pulmonary fibrosis (IPF).

The critical bedside principle: AE-ILD is a diagnosis of exclusion. Infection, pulmonary embolism, pneumothorax, and heart failure must be aggressively ruled out because they can mimic exacerbations and require completely different management.

Next, we turn to pathobiology and why these patients deteriorate so rapidly. Acute exacerbations often represent diffuse alveolar damage superimposed on chronic fibrosis, producing a clinical picture similar to ARDS. However, in some non-IPF ILDs, organizing pneumonia patterns are more common—one reason those patients may respond better to immunosuppressive therapy.

Treatment remains challenging because no therapy has definitively proven benefit in randomized trials. Corticosteroids remain the most widely used intervention, but evidence is mixed.

Recent data suggest a key difference between ILD subtypes. In non-IPF ILD, higher-dose corticosteroids (>1 mg/kg prednisone equivalent) have been associated with improved survival and lower 90-day mortality. Early tapering—reducing doses by more than 10% within the first two weeks—may further improve outcomes.

In contrast, IPF exacerbations respond less predictably, and some studies suggest high-dose steroids may increase mortality, likely because the underlying pathology is often diffuse alveolar damage rather than steroid-responsive inflammation.

One therapy that should not be used is cyclophosphamide combined with steroids, which has been shown to increase mortality in acute exacerbations of IPF.

Respiratory support becomes the next critical decision point. Many patients develop severe hypoxemic respiratory failure, but outcomes with invasive mechanical ventilation are poor.

Across multiple studies: • In-hospital mortality ranges from 66–79% in ventilated ILD patients • Only ~20% of ventilated IPF patients survive to hospital discharge

Ventilator management therefore focuses on lung-protective strategies, similar to ARDS care:

• Low tidal volumes • Plateau pressures ≤30 cm H₂O • Avoid excessive PEEP, which has been associated with worse outcomes • Careful fluid management to prevent worsening pulmonary edema

Because survival after intubation is so limited, early discussions about goals of care are essential. Noninvasive ventilation or high-flow nasal oxygen may be appropriate for selected patients who decline intubation.

Prevention is therefore critically important. Antifibrotic therapies have significantly reduced exacerbation risk in IPF.

Two major agents are used:

• Nintedanib – shown in the INPULSIS trials to reduce the risk of acute exacerbations • Pirfenidone – also associated with lower exacerbation rates in multiple studies

Meta-analyses show antifibrotics reduce the risk of acute exacerbations by roughly 37%, and nintedanib has also been approved for progressive fibrosing ILDs beyond IPF, after the INBUILD trial demonstrated substantial slowing of lung function decline.

New therapies are also emerging. The FIBRONEER-ILD trial studied nerandomilast, a novel PDE-4 inhibitor, and although the composite endpoint did not reach statistical significance, the study demonstrated a meaningful reduction in mortality, suggesting a potential future role in progressive pulmonary fibrosis.

Another key strategy is early referral for lung transplantation, particularly in patients with progressive fibrotic disease. Acute exacerbations can occur unpredictably and often represent a terminal event in advanced ILD, making transplant evaluation crucial before severe deterioration occurs.

We close with the key system moves for inpatient teams:

• Recognize sudden respiratory decline in patients with fibrotic lung disease • Confirm new bilateral ground-glass opacities on CT • Aggressively rule out infection, pulmonary embolism, and heart failure • Consider corticosteroids, particularly in non-IPF ILD • Use lung-protective ventilation if respiratory failure develops • Discuss prognosis early and involve palliative care • Ensure patients with fibrotic ILD are on antifibrotic therapy when appropriate

Acute exacerbation of ILD remains one of the most devastating events in pulmonary medicine—but early recognition, careful supportive care, and preventive antifibrotic therapy can meaningfully improve outcomes.

Status Epilepticus Evidence-Based Management and Escalation Algorithms for the Hospitalist09 Mar 202600:43:52

In this episode of Hospital Medicine Unplugged, we sprint through status epilepticus—stop the seizure fast, escalate therapy on time, protect the brain, and treat the cause before refractory disease sets in.

We begin with the modern definition that changed emergency care. Status epilepticus is now defined as ≥5 minutes of continuous seizure activity or ≥2 seizures without return to baseline. The old 30-minute threshold is obsolete because neuronal injury and benzodiazepine resistance begin early, driven by GABA receptor internalization within minutes of sustained seizure activity. That’s why treatment must begin within the first 5–10 minutes.

The stakes are high: incidence is 10–40 per 100,000 annually, with 10–20% adult mortality, rising sharply in refractory cases, elderly patients, and acute symptomatic etiologies such as stroke or hypoxic injury.

Next comes the first-line intervention—benzodiazepines within 5–10 minutes. These remain Level A evidence therapy and terminate seizures in roughly 65–70% of cases when given promptly and at adequate doses.

Three effective options: • IV lorazepam 0.1 mg/kg (max 4 mg), may repeat once • IM midazolam 10 mg (0.3 mg/kg in children) — preferred if IV access unavailable • IV diazepam 0.15 mg/kg, may repeat once

The biggest real-world mistake isn’t drug choice—it’s delay and underdosing.

If seizures persist, move quickly to second-line “urgent control” therapy (10–20 minutes). The landmark ESETT trial compared levetiracetam, fosphenytoin, and valproate in benzodiazepine-refractory status epilepticus and fundamentally changed practice.

The key finding: all three drugs work equally well, stopping seizures in about 47–52% of patients.

Recommended doses: • Levetiracetam 60 mg/kg (max 4500 mg) • Fosphenytoin 20 mg PE/kg • Valproate 40 mg/kg

Because efficacy is equivalent, patient factors guide the choice: • Cardiac disease → avoid fosphenytoin (hypotension/arrhythmia risk) • Pregnancy or liver disease → avoid valproate • Simplest safety profile → levetiracetam

Other alternatives include lacosamide or phenobarbital, though ESETT drugs remain the most widely used.

When seizures continue despite these steps, the patient has entered refractory status epilepticus, which occurs in 23–43% of cases. At this stage, escalation means ICU care, intubation, and continuous EEG monitoring.

Third-line therapy involves continuous anesthetic infusions designed to suppress cortical activity:

• Propofol (20–200 mcg/kg/min) — rapid onset but risk of propofol infusion syndrome with prolonged use • Midazolam infusion — commonly used but tachyphylaxis develops • Pentobarbital coma — powerful seizure suppression but high rates of hypotension and prolonged sedation

Most modern practice favors propofol or midazolam over barbiturate coma.

A newer strategy gaining traction is ketamine, an NMDA receptor antagonist with a completely different mechanism from GABAergic drugs. Unlike other anesthetics, ketamine preserves blood pressure and respiratory drive, making it a useful adjunct in refractory disease.

If seizures continue ≥24 hours despite anesthetic therapy, the condition becomes super-refractory status epilepticus, a devastating scenario with mortality approaching 40–50%.

Management expands to include: • Ketamine infusions • Immunotherapy (steroids, IVIG, plasmapheresis) when autoimmune etiologies are suspected • Ketogenic diet • Neuromodulation or epilepsy surgery in select cases

Two particularly challenging syndromes fall into this category: NORSE (New Onset Refractory Status Epilepticus) and FIRES (Febrile Infection-Related Epilepsy Syndrome), often requiring aggressive immunologic treatment.

Throughout all stages, clinicians must identify and treat the underlying cause—the strongest determinant of outcome.

Prognosis varies dramatically depending on response to therapy: • Benzodiazepine-responsive SE: <5% mortality • Second-line responsive SE: ~10–15% mortality • Refractory SE: 20–40% mortality • Super-refractory SE: up to 50% mortality

Poor outcomes are associated with older age, acute symptomatic etiologies (stroke, infection, hypoxic injury), prolonged seizures, and nonconvulsive status epilepticus with coma, which is one of the strongest predictors of mortality.

Finally, systems matter. Hospitals that implement structured status epilepticus protocols dramatically improve outcomes. Protocol adherence reduces time to second-line therapy from nearly an hour to about 20 minutes and lowers ICU transfer rates.

We close with the practical escalation algorithm every inpatient team should know:

• 0–5 minutes: ABCs, glucose check, IV access, prepare meds • 5–10 minutes: benzodiazepine (lorazepam, midazolam, or diazepam) • 10–20 minutes: second-line AED (levetiracetam, fosphenytoin, or valproate) • 20–40 minutes: prepare for intubation, initiate EEG monitoring • Refractory SE: continuous anesthetic infusion in the ICU • Super-refractory SE: ketamine, immunotherapy, ketogenic diet, or surgical options

Treat fast, escalate early, follow the algorithm, and search relentlessly for the underlying cause. In status epilepticus, every minute of uncontrolled seizure activity threatens the brain.

Measles: Clinical Pathology and Global Public Health Trends in the Hospitalized Patient09 Mar 202600:34:13

In this episode of Hospital Medicine Unplugged, we sprint through measles—one of the most contagious infectious diseases known—covering transmission, classic clinical presentation, complications, diagnosis, and prevention through vaccination.

We start with the big picture. Measles (rubeola) is a highly contagious viral illness caused by a paramyxovirus and remains a major global public health concern despite the availability of an effective vaccine. Clinically, the disease is defined by fever, cough, coryza, conjunctivitis, and a characteristic maculopapular rash.

After decades of progress toward elimination, measles has resurged worldwide. Global cases increased dramatically from about 132,000 cases in 2016 to nearly 870,000 in 2019, driven by large outbreaks and declining vaccination coverage. Pandemic-related disruptions to immunization programs worsened the problem, with global first-dose vaccine coverage dropping to 81% in 2021—the lowest level in more than a decade. Even in the United States, outbreaks continue to occur, with the vast majority of cases seen in unvaccinated individuals or those with unknown vaccination status.

The reason measles spreads so easily is its extraordinary transmissibility. The virus spreads through airborne respiratory droplets, and viral particles can remain suspended in the air for up to two hours after an infected person leaves the area. The basic reproduction number (R₀) is estimated at 12–18, meaning a single infected person can transmit the virus to more than a dozen susceptible individuals.

The incubation period is typically 10–14 days, and patients become contagious about four days before the rash appears and remain infectious until four days after rash onset. Because measles spreads so efficiently, achieving herd immunity requires at least 95% vaccine coverage with two doses.

Clinically, measles follows a predictable three-phase course.

First is the prodromal phase, lasting about 2–4 days. Patients develop high fever along with the “three Cs”: cough, coryza, and conjunctivitis. A key diagnostic clue during this phase is the appearance of Koplik spots—small bluish-white lesions on the buccal mucosa, which are considered pathognomonic and typically appear 1–2 days before the rash.

Next comes the exanthem phase, when the classic erythematous maculopapular rash appears. The rash begins on the face and hairline, then spreads downward to the trunk and extremities over several days. It often becomes confluent on the face and upper body before gradually fading in the same order that it appeared.

The final stage is the convalescent phase, during which symptoms gradually resolve, typically within about one week after rash onset in uncomplicated cases.

Despite this classic presentation, measles is far from benign. Approximately 30–40% of patients develop complications, particularly among infants, adults, pregnant individuals, immunocompromised patients, and malnourished children.

Common complications include: • Otitis media (about 7–9% of cases) • Pneumonia, the leading cause of measles-related death • Diarrhea and dehydration

More severe complications involve the central nervous system. Acute postinfectious encephalitis occurs in roughly 1 in 1,000 cases and carries a 20% mortality rate. Immunocompromised patients may develop measles inclusion-body encephalitis, which is nearly always fatal.

One of the most devastating complications is subacute sclerosing panencephalitis (SSPE)—a progressive degenerative brain disease that develops 7–10 years after infection. Although rare, it is universally fatal within several years of onset.

Measles also produces a phenomenon known as immune amnesia. The virus suppresses immune memory for 2–3 years, increasing vulnerability to other infections and contributing to excess mortality even after recovery from the acute illness.

Diagnosis is often suspected clinically when patients present with fever, rash, and the three Cs, especially if Koplik spots are observed. However, laboratory confirmation is essential—particularly during outbreaks or in previously vaccinated individuals who may develop modified measles with milder symptoms.

Diagnostic testing includes: • RT-PCR detection of viral RNA • Measles IgM serology using ELISA • Viral genotyping for epidemiologic surveillance

Management of measles is primarily supportive, as no specific antiviral therapy exists. Treatment focuses on hydration, fever control, nutritional support, and treatment of secondary bacterial infections.

One intervention with strong evidence is vitamin A supplementation. Clinical trials have demonstrated that vitamin A significantly reduces measles-related mortality, particularly in children. Current recommendations are to administer two age-adjusted doses of vitamin A on consecutive days, with an additional dose given later if vitamin A deficiency is suspected.

Ultimately, the most effective strategy against measles is prevention through vaccination. The MMR vaccine provides highly effective protection, with two doses achieving approximately 97% immunity.

We close with the key clinical takeaways:

• Measles is among the most contagious infectious diseases known • The classic presentation includes fever, cough, coryza, conjunctivitis, Koplik spots, and a descending maculopapular rash • Complications occur in up to 40% of cases and can include pneumonia and encephalitis • Vitamin A supplementation significantly reduces mortality in children • Maintaining ≥95% vaccination coverage is essential for herd immunity

Measles is often viewed as a childhood disease of the past—but as vaccination rates decline in some regions, clinicians must remain vigilant. Recognizing measles quickly, isolating cases, and promoting vaccination remain essential tools for preventing outbreaks and protecting vulnerable populations.

Clinical Perspectives on Acquired Aplastic Anemia Management in the Hospital Setting08 Mar 202600:31:40

In this episode of Hospital Medicine Unplugged, we sprint through aplastic anemia—recognize the pancytopenia, confirm marrow failure, suppress the immune attack, and watch for clonal evolution.

We open with the diagnostic framework that defines disease severity. The Camitta criteria remain the standard classification. Severe aplastic anemia requires bone marrow cellularity <25% plus at least two of three cytopenias: • ANC <500/μL • Platelets <20,000/μL • Reticulocytes <60,000/μL

Very severe disease is defined by ANC <200/μL, a group at extremely high infection risk. These criteria matter because treatment decisions hinge on severity, patient age, and donor availability.

Next, we unpack the pathophysiology—the immune system attacking hematopoiesis. In acquired aplastic anemia, cytotoxic T cells target hematopoietic stem and progenitor cells (HSPCs). These T cells release interferon-γ and TNF-α, which activate Fas/Fas-ligand pathways, triggering apoptosis of stem cells and collapsing bone marrow production.

Recent discoveries explain how immune escape and clonal selection occur. IFN-γ suppresses HSPCs expressing HLA class I molecules, while HLA-deficient clones evade immune destruction, creating a survival advantage in about 30% of patients. Meanwhile, regulatory T cells are decreased, and their restoration often parallels hematologic recovery.

Then comes one of the biggest therapeutic advances in decades: adding eltrombopag to immunosuppressive therapy. Standard treatment has long been horse antithymocyte globulin (ATG) plus cyclosporine, but the RACE trial changed the landscape.

When eltrombopag was added: • Complete response at 3 months doubled (22% vs 10%) • Overall response at 6 months increased to 68% vs 41% • Median time to response shortened from 8.8 months to 3 months

Because of these results, ASH 2025 guidelines now recommend eltrombopag alongside ATG and cyclosporine for severe and very severe aplastic anemia in both adults and children. Beyond thrombopoiesis, eltrombopag appears to stimulate stem-cell recovery and counteract IFN-γ–mediated suppression.

For curative therapy, we turn to hematopoietic stem cell transplantation. Modern guidelines use age-based decision pathways:

• <20 years: matched sibling transplant or immunosuppressive therapy • 20–40 years: matched unrelated donor transplant or immunosuppressive therapy • >40 years: immunosuppressive therapy preferred

Haploidentical transplant is generally reserved for later lines, with immunosuppressive therapy favored initially.

Another hallmark of aplastic anemia is its relationship with paroxysmal nocturnal hemoglobinuria (PNH). Up to 50% of patients harbor a PNH clone, detectable by FLAER-based flow cytometry with CD55/CD59 testing. Importantly, the presence of a PNH clone is actually a favorable prognostic sign.

Patients with PNH clones show: • Better response to immunosuppressive therapy (≈78% vs 50%) • Better transplant outcomes (≈97% vs 77%) • Lower risk of progression to myelodysplastic syndrome

The mechanism is elegant: GPI-negative stem cells with PIGA mutations escape immune destruction, allowing them to survive when normal HSPCs are targeted.

Despite improved survival, long-term complications remain a major concern. About 10–20% of patients develop clonal evolution to myelodysplastic syndrome or acute myeloid leukemia within 10 years, particularly after immunosuppressive therapy.

Genomic studies show clonal hematopoiesis in roughly half of patients, with mutation patterns predicting outcomes: • DNMT3A and ASXL1 → higher risk of clonal expansion and progression to MDS/AML • BCOR, BCORL1, and PIGA → better response and more stable disease

Risk factors for clonal evolution include older age, poor response to immunosuppressive therapy, high-risk mutations, and multiple mutations with higher allele burden.

When secondary myeloid malignancies occur, they often carry high-risk cytogenetics such as monosomy 7 or complex karyotypes, with ~40% five-year survival without transplant. Fortunately, allogeneic stem cell transplantation can improve survival to about 64%.

The big picture today is far more optimistic than in the past. With modern therapy—including ATG, cyclosporine, and eltrombopag—five-year survival now exceeds 80%, with some studies reporting survival approaching 97%. But relapse still occurs in about 22% of patients, making long-term monitoring essential.

We close with the system moves: confirm severe disease using Camitta criteria, suppress the immune attack with ATG + cyclosporine + eltrombopag, evaluate for transplant based on age and donor availability, screen all patients for PNH clones, and monitor closely for clonal evolution.

Aplastic anemia is no longer uniformly fatal—but recognizing the immune mechanism, treating early, and tracking clonal risk can transform outcomes for these patients.

Brugada Syndrome in the Inpatient Setting: Clinical Diagnosis and Management Strategies for the Hospitalist08 Mar 202600:36:36

In this episode of Hospital Medicine Unplugged, we sprint through Brugada syndrome—spot the ECG, stratify the risk, prevent sudden cardiac death, and avoid the triggers that unmask malignant arrhythmias.

We start with the ECG that makes the diagnosis. Type 1 Brugada pattern is the only diagnostic finding: coved ST elevation ≥2 mm in ≥1 right precordial lead (V1–V3) followed by a negative T wave. The 2013 consensus simplified the diagnosis—a Type 1 pattern alone (spontaneous or drug-induced) is sufficient, without requiring symptoms or family history. Type 2 (“saddleback”) pattern shows ≥0.5 mm ST elevation with a convex ST segment and positive T wave, but it is only suggestive, not diagnostic.

Next comes a critical inpatient pearl: Brugada ECG patterns are dynamic. They may appear and disappear and are often unmasked by fever, sodium-channel blockers, increased vagal tone, or post-prandial states. This is why hospitalized patients with unexplained syncope or fever should have careful ECG review—the pattern may only be visible transiently.

Risk stratification drives management and ICD decisions, which is one of the hardest parts of Brugada care.

High-risk patients (Class I indication for ICD): • Prior cardiac arrest or documented sustained ventricular arrhythmia • Spontaneous Type 1 ECG with syncope presumed due to ventricular arrhythmia

These patients face annual event rates of roughly 5–10%, making ICD therapy life-saving.

Intermediate risk: • Asymptomatic spontaneous Type 1 pattern (≈0.5–1.2% annual risk) • Syncope with spontaneous Type 1 pattern (≈6–19% event risk over ~2–3 years) • Fever-induced Type 1 ECG pattern

Low risk (ICD not indicated): • Asymptomatic patients with only drug-induced Type 1 pattern • Event rate <0.5% annually

A key myth to bust: family history alone does NOT reliably predict individual arrhythmic risk.

We also review BRUGADA-RISK, a modern clinical risk model incorporating ECG and clinical variables to estimate 5-year arrhythmic risk, showing strong predictive performance with ~71% sensitivity and ~80% specificity at a 10% risk threshold.

Then comes the debate over electrophysiology studies (EPS). Current guidelines give Class IIb support for programmed ventricular stimulation in asymptomatic patients with spontaneous Type 1 ECG. Inducible arrhythmias roughly double the risk of events, but the absence of inducibility does not guarantee safety, so clinical history still matters most.

When prevention matters most, remember the bottom line: ICD implantation is the only proven therapy that prevents sudden cardiac death in Brugada syndrome.

Class I indications for ICD: • Survivors of cardiac arrest • Documented spontaneous sustained VT • Spontaneous Type 1 ECG with arrhythmic syncope

For patients with recurrent ICD shocks, escalation strategies include quinidine therapy or catheter ablation targeting abnormal epicardial substrate in the RV outflow tract.

Hospital teams must also know the medications that worsen Brugada. Drugs that block cardiac sodium channels can unmask the ECG pattern and trigger ventricular arrhythmias. High-risk categories include Class IC antiarrhythmics (flecainide, propafenone), tricyclic antidepressants, lithium, certain antipsychotics, local anesthetics like bupivacaine, propofol, cocaine, and excessive alcohol. The safest move is to check brugadadrugs.org before prescribing.

Finally, one of the most important bedside pearls: fever is a powerful arrhythmic trigger in Brugada syndrome. Temperature-dependent sodium channel dysfunction can convert a silent patient into a ventricular arrhythmia emergency. That’s why aggressive antipyretic therapy is mandatory in any febrile Brugada patient—especially in children and hospitalized patients.

We close with the take-home system moves: recognize the Type 1 ECG pattern, treat fever aggressively, avoid sodium-channel-blocking medications, risk-stratify carefully, and implant ICDs in the right patients.

Brugada syndrome may hide in plain sight—but once you know the ECG and the triggers, you can identify risk early and prevent sudden cardiac death.

When Safety Becomes Harm and Why Less Is More. The Evidence, Ethics, and Hidden Harms of Hospital Restraints26 Dec 202500:39:55

In this episode of Hospital Medicine Unplugged, we tackle one of the most ethically charged and clinically challenging topics in inpatient care: the use of restraints in the hospital setting. When are restraints justified, why do we still use them so often, and what does the evidence actually show about benefit versus harm?

We start by defining physical restraints—any device or method that limits a patient’s movement, from wrist and ankle restraints to vests, belts, bed rails, and enclosure beds—and chemical restraints, medications used primarily to control behavior rather than treat an underlying condition. We unpack why experts increasingly reject the term “chemical restraint,” emphasizing pharmacologic treatment of agitation aimed at calming, not sedating, patients while addressing root causes.

Next, we explore why restraints are used: fall prevention, prevention of device removal, management of delirium or agitation, and protection of staff. But here’s the paradox—observational data consistently show higher rates of the very outcomes restraints are meant to prevent, including unplanned extubations, device removal, increased agitation, delirium, and longer ICU stays.

We break down the scope of the problem. Nearly 1 in 10 hospitalized patients experiences restraint use, with rates approaching 40% of ICU encounters and even higher among mechanically ventilated patients. Use varies widely by setting, staffing, and culture—highlighting that restraint use is often system-driven, not patient-driven.

The heart of the episode focuses on ethics and law. Restraints represent a profound restriction of liberty, and ethical use requires three conditions: medical appropriateness, informed consent (or a valid emergency exception), and use of the least restrictive option. We review federal regulatory requirements—restraints only for imminent harm, after less restrictive measures fail, time-limited orders, mandatory face-to-face evaluations, continuous monitoring, and early removal.

We then confront the real harms. Physically: DVT, PE, aspiration pneumonia, fractures, pressure injuries, rhabdomyolysis, asphyxiation, and death. Psychologically: fear, loss of dignity, and PTSD, affecting up to 25–47% of patients after a restraint event. These risks rise with each additional day of restraint use.

From there, we pivot to what actually works: alternatives. Multicomponent, non-pharmacologic strategies—reorientation, sleep hygiene, pain control, early mobility, family engagement, sitters, sensory optimization, and delirium prevention bundles like ABCDEF—reduce delirium and restraint use by 40–60% while improving outcomes.

We close with practical takeaways: assess underlying causes first (pain, hypoxia, infection, withdrawal, delirium), use verbal de-escalation and environment before meds, reserve restraints for true emergencies, document meticulously, reassess relentlessly, and remove early. The bottom line: restraints are not benign, not preventive, and not routine care—they are a last resort in modern, patient-centered hospital medicine.

Fast, evidence-driven, and ethically grounded—protect safety without sacrificing dignity.

Management of Dementia with Behavioral and Psychological Symptoms of Dementia (BPSD) in Acute Hospital Care: Taming Agitation Without Making It Worse26 Dec 202500:27:00

In this episode of Hospital Medicine Unplugged, we tackle dementia with behavioral and psychological symptoms (BPSD) in the hospitalized patient—why it happens, how to assess it fast, and how to manage it safely without making things worse.

We start with the big picture: BPSD affects >90% of people with dementia, often driving hospital admissions. Symptoms span agitation, aggression, psychosis, depression, anxiety, apathy, sleep disturbance, and disinhibition—and they’re not benign. In the hospital, BPSD is linked to longer stays, higher mortality, restraint use, staff injury, early institutionalization, and one-third of total dementia care costs.

Next, we walk through the do-first inpatient assessment. Rule out delirium (acute onset, fluctuating attention), then hunt for reversible triggers: pain, constipation, urinary retention, infection, hypoxia, metabolic derangements, sleep disruption, and iatrogenic harm from polypharmacy—especially anticholinergics, benzodiazepines, and opioids. Collateral history is critical to establish baseline behavior. Use structured tools like CAM/4AT for delirium, PAINAD for nonverbal pain, and NPI or CMAI to quantify symptoms. The DICE approach (Describe–Investigate–Create–Evaluate) keeps management personalized and efficient.

We emphasize that non-pharmacologic strategies are first-line—always. In the hospital, this means person-centered care: reorientation, sleep hygiene, early mobility, sensory optimization (glasses/hearing aids), hydration, toileting, nutrition, and calm communication. Caregiver- and staff-focused interventions have the strongest evidence, reducing both symptom burden and distress. Music therapy, tailored activities, exercise, massage/touch, and multicomponent delirium programs like HELP can meaningfully reduce agitation and prevent escalation.

When symptoms threaten safety, we cover how to use meds sparingly and smartly. Before adding anything, do a medication cleanup. Pharmacotherapy is time-limited, lowest dose, shortest duration, and always paired with non-drug strategies. • Cholinesterase inhibitors can modestly improve BPSD over time. • Antipsychotics offer small benefits for severe agitation or psychosis but carry real risks—increased mortality, stroke, sedation, EPS, QT prolongation, and functional decline. No clear winner among agents. Use hours to days, reassess daily, and document risk–benefit discussions. Avoid dopamine blockers in Lewy body dementia; if unavoidable, extreme caution. • SSRIs help depression/anxiety; evidence for agitation is limited. Mirtazapine doesn’t help agitation. • Benzodiazepines and valproate are generally avoid. • Pain control matters—untreated pain fuels agitation.

We close with hospital pearls: no routine drugs for delirium; antipsychotics only for dangerous behaviors refractory to non-drug care. Plan early for deprescribing—one-third of patients started on antipsychotics in the hospital leave on them unless you stop it. At discharge, communicate what worked: triggers, de-escalation strategies, sleep plans, toileting schedules, and a clear reassessment plan. Align care with goals, dignity, and function.

Bottom line: Treat the cause, lead with non-pharmacologic care, reserve meds for safety, reassess relentlessly, and deprescribe early.

Bell's Palsy Versus Stroke: Inpatient Diagnosis and Management26 Dec 202500:39:51

In this episode of Hospital Medicine Unplugged, we tackle one of the most anxiety-provoking inpatient consults: acute facial weakness—Bell’s palsy or stroke? We break down how to tell them apart fast, why the distinction matters, and how to manage each safely in hospitalized patients.

We start with the bedside exam that saves lives. Forehead involvement = peripheral (Bell’s palsy); forehead sparing = central (stroke)—until proven otherwise. Bell’s palsy presents with acute unilateral facial paralysis involving the forehead, often peaking within 72 hours, and may include post-auricular pain, altered taste, hyperacusis, or dry eye, without other neurologic deficits. Stroke typically hits suddenly, often spares the forehead, and comes with red flags like limb weakness, aphasia, gaze deviation, dysphagia, or altered mental status.

We walk through the don’t-miss pitfalls: brainstem strokes that mimic a lower motor neuron pattern, bilateral facial weakness, gradual or progressive onset, recurrent ipsilateral palsy, hearing loss or vertigo, and facial palsy in post-op, ICU, immunocompromised, or cancer patients—all of which demand a lower threshold for imaging and expanded workup.

Next, the inpatient diagnostic strategy. Suspect stroke? Activate the stroke alert—determine last known well, check glucose, perform a focused neuro exam, and get emergent CT/MRI. For classic Bell’s palsy, routine labs and imaging aren’t required, but in hospitalized patients consider MRI with contrast or CSF if there are atypical features, infection risk, multiple cranial nerves involved, or no improvement by 3–6 weeks.

Treatment pearls you can use today: Bell’s palsy—start oral corticosteroids within 72 hours (prednisone 50–60 mg daily x5 days, then taper). This improves complete recovery (NNT ≈10). Antivirals alone don’t work; adding them to steroids may modestly reduce synkinesis, especially in severe paralysis. Eye protection is non-negotiable: artificial tears, nighttime ointment, and a moisture shield—early ophthalmology if exposure risk. Stroke—time is brain. Eligible patients get IV thrombolysis and/or mechanical thrombectomy based on time and imaging, with guideline-directed blood pressure control, antithrombotics, and early rehab.

We close with prognosis and counseling. Bell’s palsy has a 70–85% complete recovery rate (higher with early steroids), but 25–40% may have residual weakness or synkinesis—plan follow-up at 3 months if recovery lags. Stroke outcomes hinge on severity and speed to reperfusion, making rapid recognition critical.

Bottom line: Examine the forehead, hunt for red flags, image early when in doubt, protect the eye, treat fast, and never miss a stroke.

Aspirin Alone or Dual Antiplatelet Therapy (DAPT) with Clopidogrel? The Hospitalist's Guide to Early Stroke Recurrence Prevention06 Dec 202500:31:35

In this episode of Hospital Medicine Unplugged, we get practical about single vs dual antiplatelet therapy after ischemic stroke—who gets what, for how long, and when DAPT does more harm than good.

We start by framing the landscape: noncardioembolic vs cardioembolic stroke, small-vessel vs large-artery disease, and why platelets are center stage in atherothrombotic stroke but not in AF-driven cardioembolism.

Then we walk through who actually qualifies for DAPT:

  • Minor noncardioembolic ischemic stroke (NIHSS ≤3)

  • High-risk TIA (ABCD² ≥4)

  • Select mild-to-moderate strokes (up to NIHSS 5) and large-artery atherosclerosis / intracranial stenosis, where data for intensified therapy are emerging.

We lay out exact protocols you can copy into your order sets:

  • Classic aspirin + clopidogrel: loading, maintenance, and how to transition cleanly to SAPT.

  • Ticagrelor + aspirin: when to prefer it (e.g., CYP2C19 loss-of-function) and how to factor in the higher bleeding signal.

  • Why triple therapy is a hard no.

A big chunk of the episode is “how long is long enough?”:

  • Why the real benefit of DAPT is front-loaded into the first 10–21 days.

  • How CHANCE, POINT, THALES, and meta-analyses sharpen the message: short-term DAPT cuts early recurrence; longer DAPT mainly buys bleeding.

  • Why most patients should land on ~21 days of DAPT, then SAPT indefinitely, and when 30–90 days might still make sense (e.g., intracranial stenosis, stenting protocols).

We also spell out when NOT to use DAPT:

  • Moderate–severe stroke with big infarcts and hemorrhagic risk

  • Cardioembolic stroke (AF, LV thrombus, valvular disease) where anticoagulation wins

  • Lacunar stroke, where SPS3 showed more bleeding without benefit

  • Patients with high bleeding risk or prior GI bleed, thrombocytopenia, or hemorrhagic transformation

  • ESUS and other gray zones where DAPT has no proven upside.

Finally, we zoom out to long-term secondary prevention:

  • Choosing between aspirin, clopidogrel, and aspirin–dipyridamole

  • Why clopidogrel often has the best net clinical profile (similar efficacy, less major bleeding)

  • How to build a stroke unit habit: NIHSS + ABCD² on arrival, early mechanism workup, tight DAPT stop dates, and defaulting back to SAPT instead of “set-and-forget” dual therapy.

If you’ve ever wondered “Should this patient be on DAPT, for how long, and what am I risking?” this episode gives you a crisp, evidence-based playbook you can use on your next stroke admission.

To Bridge or Not to Bridge: Perioperative Anticoagulation Bridging Risks, Guidelines, and Strategies in Hospitalized Patients06 Dec 202500:34:14

In this episode of Hospital Medicine Unplugged, we hit the brakes on routine bridging—who actually needs LMWH/UFH when you stop warfarin, and who is safer with no bridge at all?

We start by nailing the definition: bridging = temporarily swapping a long-acting oral anticoagulant (usually warfarin) for short-acting heparin (UFH/LMWH) during interruptions for procedures or bleeding. Then we zoom out to the core tension: tiny peri-procedural thromboembolic risk vs a 3–4× jump in major bleeding with bridging.

We walk through thromboembolic risk stratification—AF with CHA₂DS₂-VASc, recent VTE timing, mechanical valves, and severe thrombophilia—and pair it with procedure and patient bleeding risk (neurosurgery vs dental work, HAS-BLED factors, renal/liver disease, prior bleeds).

Then comes the evidence gut-punch:

  • BRIDGE: in AF on warfarin, no reduction in thromboembolism, but major bleeding triples with LMWH bridging.

  • Meta-analyses: no thrombotic benefit, big bleeding signal across mixed AF/VTE/mechanical valve cohorts.

  • PAUSE & DOAC data: rapid onset/offset means DOACs almost never need bridging.

From there we carve out the true bridging exceptions—the “maybe yes” group: • Mechanical mitral or older-generation mechanical valves • Very recent (<3 months) VTE or stroke/systemic embolism • Severe thrombophilia or high-risk cancer-associated VTE

Everywhere else, guidelines increasingly say: “Don’t bridge.” Most AF, remote VTE, bileaflet mechanical AVR without extra risk factors, and all DOAC-treated patients go down a simple interrupt-and-restart pathway instead of heparin drips and syringes.

We close with a practical, ward-ready playbook: • Step 1: Classify thromboembolic risk (AF/VTE/valve). • Step 2: Classify procedure + patient bleeding risk. • Step 3: If DOAC → timed hold based on drug + kidney function, no bridge. • Step 4: If warfarin and truly very high thrombotic risk → consider LMWH/UFH, but delay/avoid post-op therapeutic dosing when bleeding risk is high. • Step 5: Use prophylactic-dose LMWH as VTE prophylaxis, not as a stealth “mini-bridge.”

By the end, you’ll have a clean mental algorithm for “bridge vs no bridge” that lines up with ACCP, AHA/ACC, and AF guidelines—less bleeding, same stroke protection, and far fewer unnecessary heparin shots.

The Hospitalist's Guide to Inpatient Anticoagulation: Choose Fast, Dose Smart, Avoid Disaster06 Dec 202500:32:10

In this episode of Hospital Medicine Unplugged, we run the inpatient anticoagulation playbook—pick the right drug, dose it safely, and dodge both clots and bleeds.

We start with why we anticoagulate in hospital: VTE treatment and prophylaxis, AF stroke prevention, ACS, and valve/bridging scenarios—always walking the tightrope between thrombosis and bleeding. Then we map the four main drug classes: • DOACs as default for most nonvalvular AF and VTE—rapid onset, predictable PK, no routine monitoring, but no go in mechanical valves, APS, pregnancy, or severe CKD. • LMWH as the inpatient workhorse—VTE treatment and prophylaxis, cancer, pregnancy, lower HIT and osteoporosis risk, but renally cleared and only partially reversible. • UFH as the rescue drug—severe renal failure, high bleeding risk, need for rapid on/off, thrombolysis, or upcoming procedures. • Warfarin for the “can’t DOAC” crowd—mechanical valves, rheumatic MS, triple-positive APS, advanced CKD/liver disease—with INR targets, monitoring, and all the interaction baggage.

From there we build a clinical decision framework: • Renal and hepatic function drive DOAC vs LMWH vs UFH vs warfarin. • Bleeding risk (HAS-BLED, IMPROVE) and prior GI bleed shape how hard you push. • Drug–drug interactions (CYP3A4/P-gp, polypharmacy, antiplatelets/NSAIDs) push you toward or away from certain DOACs or warfarin. • Extremes of body weight, procedures on the horizon, and the need for a reversal plan all feed into the choice.

For VTE treatment, we compare: • Stable DVT/PE with good kidneys → DOAC first (EINSTEIN, AMPLIFY, Hokusai). • Cancer-associated VTE → DOACs vs LMWH: DOACs now common, but LMWH still preferred for GI/GU tumors or very high bleeding risk. • Severe CKD or tenuous bleeder → UFH infusion with aPTT-guided titration and protamine in your back pocket. • Mechanical valves or APS → warfarin with bridging.

For VTE prophylaxis, we keep it practical: • LMWH (enoxaparin/dalteparin) as first-line in most medical/surgical inpatients. • UFH for CrCl <30 or when you need a super short half-life. • DOACs (rivaroxaban, betrixaban) as select tools for extended prophylaxis, not routine inpatient starters. • Warfarin stays out of acute prophylaxis.

We also tackle cardiology use cases: • UFH (or bivalirudin) for ACS/PCI. • Enoxaparin as an alternative in NSTE-ACS/unstable angina when managed medically. • DOACs and warfarin move to the long-game: AF, LV thrombus, and post-ACS patients who need both antiplatelets and anticoagulation.

Finally, we walk through special populations: • Severe CKD → UFH first; dose-reduced LMWH or off-label apixaban only with eyes wide open. • Morbid obesity or very low weight → how we think about fixed-dose DOACs, weight-based LMWH, and when to consider anti-Xa levels. • Pregnancy → LMWH only, no DOACs or warfarin. • Cancer → choosing between DOACs and LMWH based on tumor site, bleeding risk, kidneys, and patient preferences.

We close with a bedside checklist: define the indication, check kidney/liver function, estimate bleeding risk, scan the med list for interactions, ask “how fast do I need on/off?”, then lock in an agent, dose, monitoring plan, and a clear reversal strategy. Right drug, right patient, right moment—while keeping both clots and bleeds off your service list.

Anemia Diagnosis and Management in the Hospitalized Patient: How to Differentiate between Iron-Deficiency Anemia and Anemia of Chronic Disease06 Dec 202500:32:30

In this episode of Hospital Medicine Unplugged, we unpack iron deficiency anemia (IDA) and anemia of chronic disease/inflammation (ACD/AI)—absolute iron depletion versus hepcidin-driven iron lock-down, and why that distinction matters on the wards.

We sprint through the core physiology: IDA runs on empty iron stores—low ferritin, low TSAT, low hepcidin, microcytosis. ACD/AI keeps iron trapped inside macrophages—normal/high ferritin, low TSAT, low transferrin, high hepcidin—producing a functional deficiency despite adequate stores.

Diagnosis starts with the do-first labs: CBC with indices, smear, ferritin, serum iron, TIBC, TSAT, CRP, ± soluble transferrin receptor (sTfR) and reticulocyte Hb. Ferritin <30 ng/mL screams IDA, but in inflammation we need a higher cutoff (<100). sTfR high = IDA; normal = ACD/AI. Hepcidin stays low in IDA, high in ACD.

Symptom patterns help but aren’t definitive: IDA brings classic iron-depletion clues (pica, restless legs, glossitis), while ACD/AI blends into the underlying chronic disease. Overlap syndromes blur the picture—ferritin “normal,” TSAT low, inflammation high—the most common and the most misdiagnosed group in the hospital.

Management stays principle-driven: • Treat the cause first—stop the bleed, fix malabsorption, control inflammation. • Replete iron: oral every-other-day for pure IDA; IV iron for inflammation, malabsorption, or rapid repletion needs. • ACD/AI leans on underlying disease control; ESA therapy only in selected CKD/cancer patients. • Overlap syndromes? Think IV iron early; oral will fail against hepcidin.

Risk matters: anemia on admission predicts longer stay, higher readmission, and higher mortality. The sickest group—older adults with multiple comorbidities—often has mixed pathology and needs aggressive evaluation and structured follow-up every 3–6 months with CBC and iron studies.

We close with future directions: hepcidin antagonists, HIF-PH inhibitors, and precision biomarkers (hepcidin, sTfR) that may finally crack the code of inflammation-mediated iron restriction. For now, stick to the fundamentals: identify absolute vs functional deficiency, interpret ferritin through the lens of inflammation, choose the right route for iron, and never overlook an “inappropriately normal” ferritin.

The Against Medical Advice (AMA) Discharge of the Hospitalized Patient: Risks, Ethics, and Best Practices06 Dec 202500:41:15

In this episode of Hospital Medicine Unplugged, we crack open Against Medical Advice (AMA) discharges—why patients walk, who’s at highest risk, what really happens after they leave, and how to respond in a way that’s ethical, patient-centered, and legally defensible.

We start with the basics: AMA = patients leaving before the team thinks it’s safe. It’s only ~1–2% of discharges, but clustered in younger patients, men, people with substance use and psychiatric disorders, those who are uninsured, on Medicaid, or homeless, and especially anyone with a prior AMA history. We unpack how structural factors—poverty, racism, housing instability, insurance gaps—drive “noncompliance” more than patient personality.

Then we lay out the consequences: ~2× higher 30-day readmissions, a 2×+ bump in mortality, tons of early bounce-backs within 24 hours, and hundreds of thousands of hospital days and dollars burned. We connect the dots: shortened LOS, interrupted treatment, no meds, no follow-up, and patients showing up sicker at a different hospital.

From there we get practical at the bedside:

  • Capacity, always first. We walk through the 4 pillars—understanding, appreciation, reasoning, choice—and how to optimize capacity by treating delirium, intoxication, withdrawal, pain, and metabolic derangements before you even think about AMA.

  • Risk stratification by diagnosis: MI, sepsis, DKA, respiratory failure, trauma, psychiatric emergencies—what leaving early actually means for morbidity and mortality in each bucket.

  • Find the modifiable drivers: undertreated pain, unmanaged withdrawal, nicotine craving, childcare, job loss fears, transportation, homelessness, mistrust, and prior bad experiences with the system.

Communication is the pivot. We lean into nonjudgmental, empathic conversations, motivational interviewing, and de-escalation. We break down the AIMED framework—Assess, Investigate, Mitigate, Explain, Document—as a stepwise way to turn “I’m leaving” into “How can we make this safer?” without coercion or power struggles.

For high-risk groups with OUD and other SUDs, we focus on what actually moves the needle:

  • Early, in-hospital MOUD (buprenorphine/methadone) to cut AMA and readmissions.

  • Aggressive pain and withdrawal management, not just PRN clonidine.

  • Addiction consult services to initiate MOUD, link to OTPs/bridge clinics, and coordinate post-discharge care.

We zoom out to operational fixes: better discharge communication, individualized discharge plans, streamlined prescriptions, solving basics like transportation and childcare, and targeted workflows in high-risk units (ED, medicine, psych).

Then we get into documentation and legal protection—what has to be in the note so “AMA” actually means something:

  • Explicit capacity assessment (by element).

  • Concrete risks, benefits, and alternatives discussed (including partial treatment).

  • What the team offered to mitigate harm (pain control, MOUD, rides, follow-up).

  • The patient’s reasons in their own words.

  • Why the team judged the plan clinically reasonable at the time.

We stress the limits of AMA forms and why the contemporaneous narrative note, free of stigmatizing language, is your real medicolegal shield.

Finally, we tackle ethics and high-risk scenarios: autonomy vs beneficence, when persuasion becomes coercion, the difference between capacity and legal competence, and how AMA is different for minors, patients on involuntary holds, or those with guardianships. We close with harm-reduction discharges—provisional prescriptions, naloxone, wound supplies, rapid follow-up—and how to welcome patients back after an AMA episode without shame or blame.

Fast, structured, and equity-focused—identify who’s likely to leave, fix what’s fixable, communicate without stigma, build harm-reduction exits, document like it matters, and never confuse “AMA” with “we’re done caring.”

Resistant Hypertension in the Hospitalized Patient: Cutting Through Pseudoresistance, Volume Overload, and Aldosterone to Get BP Under Control05 Dec 202500:25:51

In this episode of Hospital Medicine Unplugged, we dive into evidence-based, hospital-focused management of resistant hypertension—a condition affecting up to 1 in 5 hypertensive adults and carrying ≥50% higher risk of MI, stroke, ESKD, and cardiovascular death.

We start by drawing the line between true resistant hypertension (BP above goal despite 3 complementary agents including a diuretic, or controlled BP on ≥4 meds) and the look-alikes: refractory HTN (uncontrolled on ≥5 agents including an MRA) and malignant HTN (acute end-organ damage). In the hospital, we must separate chronic resistant HTN from acutely uncontrolled BP driven by pain, anxiety, missed meds, volume shifts, or acute illness.

Our first task: rule out pseudoresistance. That means fixing measurement errors, restarting home meds, identifying nonadherence, assessing pain and volume status, and removing BP-raising drugs—NSAIDs, steroids, sympathomimetics, calcineurin inhibitors, erythropoietin, excess IV fluids, and more. We emphasize the ACC/AHA message: 20% of hypertensive adults regularly take interfering medications, and up to 41% of hospitalized patients miss home antihypertensives.

Next, we confirm true resistance with out-of-office BP—home BP or, ideally, ABPM, since white-coat resistant HTN carries far lower long-term cardiovascular risk than true resistance. If the numbers hold, we move into systematic secondary evaluation: primary aldosteronism, OSA, renal parenchymal disease, renovascular disease, and medication-induced hypertension.

Treatment opens with the guideline-backed triple therapy backbone: • ACE-I/ARB + long-acting CCB + thiazide-like diuretic (chlorthalidone/indapamide preferred). • Below eGFR 40–45: switch thiazides to loop diuretics, typically q12h dosing.

Then we deploy the fourth-line star: spironolactone 25–50 mg, the most effective agent based on RCTs and network meta-analyses, cutting 24-hour SBP by ~7–9 mm Hg. But since 4–40% cannot tolerate spironolactone, we cover alternatives: • Amiloride (10–20 mg)—equally effective in trials • Eplerenone—better tolerated hormonally, less potent BP reduction • Consider finerenone in CKD with albuminuria (role in resistant HTN still emerging)

For fifth-line therapy, we reserve beta-blockers, alpha-blockers, clonidine, and direct vasodilators—but hydralazine/minoxidil must be paired with a β-blocker + loop diuretic to blunt reflex tachycardia and fluid retention.

We also break down renal denervation, which offers modest (~3–5 mm Hg) 24-hour SBP reduction but lacks long-term CVD outcome data. Aprocitentan, FDA-approved in 2025, adds another option, though edema (9–18%) limits use in volume-sensitive patients.

CKD deserves its own playbook: resistant HTN is twice as common in CKD, thiazides lose power as GFR falls, and aldosterone excess plus sympathetic activation fuel volume-driven hypertension. We outline strategies including loop diuretics, cautious low-dose MRAs with potassium binders, and the evolving role of nonsteroidal MRAs.

Throughout, we reinforce that intensive BP control matters. For resistant HTN, pooled SPRINT/ACCORD analyses show similar benefit from a systolic target <120 mm Hg—when tolerated—cutting major CV events and mortality.

We close with a hospital-ready framework: • Fix pseudoresistance first—measurement, meds, volume, pain, interfering agents • Confirm with out-of-office BP • Screen systematically for secondary causes • Build the ACE/ARB + CCB + potent diuretic foundation • Add spironolactone, or amiloride/ eplerenone when needed • Use advanced agents and devices selectively • Individualize BP targets while avoiding overcorrection of asymptomatic inpatient BP spikes

Volume control, aldosterone blockade, clean med lists, and accurate BP data—that’s how you turn apparent chaos into controlled, evidence-based management of resistant hypertension in the hospital.

Managing Opioid Use Disorder (OUD) and Withdrawal in the Fentanyl-Era: Fast, Compassionate Inpatient Management That Keeps Patients Safe05 Dec 202500:36:35

In this episode of Hospital Medicine Unplugged, we tackle opioid withdrawal on the inpatient ward—a syndrome that’s not usually lethal, but absolutely destabilizing, deeply uncomfortable, and a leading driver of patient-directed discharge.

We open with why this matters now: fentanyl has changed everything. Its high potency and lipophilicity make withdrawal more severe, more unpredictable, and often prolonged, leaving standard opioid agonist approaches underpowered. Add in common polysubstance use—stimulants, benzodiazepines, xylazine—and clinicians must often manage multiple withdrawal syndromes in parallel.

Diagnosis starts with timing: 8–12 hours after short-acting opioids, 8–24 hours after fentanyl, up to 30 hours after methadone. Patients present with the classic multisystem storm—autonomic activation (sweating, tachycardia, piloerection, dilated pupils), GI distress, myalgias, and intense craving. We rely on COWS and SOWS for objective tracking; SOWS often detects symptoms earlier, COWS guides treatment thresholds.

But step one is simple: ask about withdrawal and treat it aggressively. Untreated withdrawal drives AMA discharges, worsens medical illness, and erodes trust. Starting MOUD early lowers AMA discharge risk by ~27%.

Treatment goals are clear: rapid symptom relief, stabilize with opioid agonists, prevent complications, and set up continuity of care.

Our backbone: opioid agonist therapy.

• Methadone shines here—no need to wait for withdrawal, no risk of precipitated withdrawal, and a full agonist profile that suits high-tolerance fentanyl users. Standard starts (20–30 mg/day) often fall short in the fentanyl era; rapid inpatient titration is increasingly used safely under monitoring. Watch QTc and delayed respiratory depression.

• Buprenorphine brings a stellar safety profile and easy outpatient continuation. But it demands mild–moderate withdrawal (COWS >10) to avoid precipitated withdrawal—still a real fear among fentanyl-exposed patients. Enter microdosing/low-dose induction, now routinely used to bridge patients onto buprenorphine without requiring abstinence.

• Some centers use slow-release oral morphine for patients with QTc issues or previous induction failures, and emerging inpatient data support short-acting full-agonist opioids as adjuncts for severe fentanyl withdrawal when standard regimens aren’t enough.

If patients decline opioid agonists, we move to symptom-targeted therapy:

• Alpha-2 agonists (clonidine, lofexidine) reduce autonomic symptoms; lofexidine offers less hypotension. • GI agents (loperamide, ondansetron, dicyclomine) smooth out the abdominal churn. • NSAIDs/acetaminophen ease myalgias; trazodone or cautious benzodiazepine use can support sleep and anxiety. But remember—non-opioid therapy alone is inferior and reserved for patients who decline MOUD.

The differential stays broad: alcohol or benzodiazepine withdrawal, stimulant intoxication, viral GI illness, thyroid storm, adrenal crisis, and sepsis, especially in people who inject drugs. Missing these can be disastrous, so vitals, exam, and targeted labs remain central.

We close with the systems moves that make withdrawal care consistent and safe: normalize withdrawal screening, default to MOUD first, incorporate COWS/SOWS into nursing workflows, build fentanyl-aware induction pathways, manage concurrent withdrawals, and hard-wire outpatient linkage—OTP confirmation lines, buprenorphine follow-up, and harm-reduction resources.

Fast, compassionate, and evidence-driven—treat withdrawal early, stabilize with MOUD, support symptoms, and never miss a life-threatening mimic.

Blood Transfusion Guidelines in the Hospitalized Patient: Modern Hospital Blood Practice, Restrictive Strategies, and the Ethics That Shape Them05 Dec 202500:38:38

In this episode of Hospital Medicine Unplugged, we plug into evidence-based blood transfusion—who really needs blood, how much, and when a “top-up” quietly harms more than it helps.

We start with the big pivot: why modern practice has moved to a restrictive transfusion strategy (Hb <7 g/dL for most hemodynamically stable adults) and what the RCTs and Cochrane data actually show. We walk through nuanced thresholds for cardiac and orthopedic surgery, preexisting cardiovascular disease, ICU patients, kids, and hematologic/oncologic populations, and flag key exceptions like GI bleeding and brain injury, where the rules bend.

Then we zoom out to the menu of components: RBCs for oxygen delivery, platelets for thrombocytopenia, plasma for true coagulopathy, cryo/fibrinogen for hypofibrinogenemia, and whole blood in massive hemorrhage. We hammer home indications beyond “just the number”—symptoms, hemodynamics, rate of Hb drop, volume status—and when NOT to transfuse: mildly abnormal INRs, “just-in-case” platelets, and procedure prophylaxis that doesn’t move bleeding risk.

Massive hemorrhage gets its own sprint: what actually defines a massive transfusion, when to trigger an MTP, why balanced 1:1:1 resuscitation (RBC:plasma:platelets) improves hemorrhage control, and how to layer in TXA, calcium, fibrinogen replacement, and viscoelastic testing (TEG/ROTEM) without drowning the patient in crystalloid.

We unpack the dark side of blood: TACO, TRALI, acute and delayed hemolytic reactions, TA-GVHD, alloimmunization, and iron overload—and how restrictive thresholds, leukoreduction, irradiation, careful dosing, and slower infusion rates slash those risks. You’ll get a practical mental checklist for “this patient is getting worse during transfusion—now what?”

Zooming up to the system level, we build a patient blood management (PBM) toolkit: Choosing Wisely-aligned thresholds, single-unit RBC default with “transfuse 1, then reassess,” EMR best-practice alerts, audit-and-feedback reports, and multidisciplinary transfusion committees that actually change culture and save thousands of units (and dollars).

We close on ethics and patient-centered care: informed consent that’s real, not scripted, transfusion decisions in frail or terminally ill patients, and caring for Jehovah’s Witness and other transfusion-refusing patients using IV iron, ESAs, cell salvage, hemostatic agents, and meticulous blood conservation—respecting autonomy while still practicing high-value medicine.

Restrictive, thoughtful, system-aware, and patient-centered—this episode is your playbook to give blood when it heals, withhold it when it harms, and always know why you’re hanging that unit.

Malnutrition in the Hospitalized Patient: Diagnosis and Assessment of Unintentional Weight Loss and Malnutrition05 Dec 202500:32:45

In this episode of Hospital Medicine Unplugged, we take a rapid, evidence-packed tour through unintentional weight loss (UWL) in hospitalized patients—screen fast, diagnose with structure, separate fluid from true tissue loss, and never miss the reversible causes.

We open with the do-firsts: screen within 24–48 hours using MUST, NRS-2002, SNAQ, or MST; older adults get the MNA-SF. Positive screen? Move straight into GLIM—you need ≥1 phenotypic + ≥1 etiologic criterion before calling malnutrition.

Phenotypics: weight loss >5% in 6 months or >10% beyond, low BMI (<20 if <70 years; <22 if ≥70), or reduced muscle mass (BIA, DXA, CT, ultrasound). Etiologics: reduced intake/assimilation or inflammation/disease burden—the cytokine-driven catabolic engine that overrides normal starvation physiology.

We highlight the epidemiology: UWL hits 20–50% of hospitalized older adults and drives higher mortality, LOS, functional decline, and readmissions—often independent of disease severity. Causes cluster into malignancy, GI disease, psychiatric disease, endocrine disorders, chronic infections, and a surprisingly large fraction (6–28%) with no clear etiology even after thorough workup.

Then the diagnostic sprint: CBC, BMP/CMP, LFTs, ultrasensitive TSH, CRP/ESR, LDH, UA, and age-appropriate cancer screenings. Chest radiography + fecal occult blood testing are universal; abdominal ultrasound or CT follows red flags. GI symptoms trigger stool culture, O&P, C. diff, malabsorption labs, or endoscopy. Never trust albumin or prealbumin—they track inflammation, not nutrition.

We hit the pitfalls hard: fluid shifts mimic weight loss, medications blunt taste and appetite, oral/dental disease gets missed, dysphagia hides in plain sight, and depression in older adults presents without sadness. EPI masquerades as IBS or celiac. Adrenal insufficiency is chronically underdiagnosed. Thyroid–diabetes interactions derail metabolic signals. Failure to screen early, recheck every 7–10 days, or document true intake leads to cascading errors.

Management? Treat the cause and build the nutritional core. Energy 20–30 kcal/kg and protein 0.8–1.5 g/kg, tailored to inflammation severity. For confirmed malnutrition, dietitian-led counseling + fortified oral supplements improve outcomes across major RCTs. Medication reconciliation is mandatory; polypharmacy wrecks appetite. Address oral pain, dentition, dysphagia, and social barriers.

We zoom in on hospital-acquired malnutrition—driven by fasting orders, mealtime interruptions, poor food service quality, inadequate feeding assistance, multimorbidity, and long LOS. Solutions use organizational muscle: protected mealtimes, dietitian-MD collaboration, patient-centered menus, protocolized swallow evaluation, early mobility, and automated rescreening.

For complex cases, we pull in the consultants: • GI for EPI, celiac, IBD, structural lesions • Endocrinology for thyroid disease, diabetes interactions, adrenal insufficiency • Psychiatry for depression, appetite changes, cognitive decline • ID for TB, HIV, chronic infections • Nutrition for intake monitoring, body composition, and intervention planning

We close with the system moves: a UWL bundle that (1) screen-within-48h defaults; (2) GLIM-confirmation pathways; (3) early imaging + stool studies when indicated; (4) intake-tracking dashboards; (5) medication-effect flags; (6) fluid-vs-tissue differentiation via calf circumference + composition tools; (7) 7–10-day reassessment; (8) multidisciplinary escalation; and (9) cause-specific tracks (malabsorption, malignancy, endocrine, psychiatric).

Fast, structured, and inflammation-aware—screen early, diagnose precisely, distinguish fluid from tissue, treat the cause, and don’t let hospital factors sabotage recovery.

Hospital Falls: Risk, Assessment, and Prevention Strategies05 Dec 202500:33:31

In this episode of Hospital Medicine Unplugged, we tackle in-hospital falls—how often they happen, why they’re so devastating, and how to build a multifactorial, restraint-sparing prevention bundle that actually works at the bedside.

We start with the scope: typical acute-care fall rates run 1.5–4.2 falls per 1,000 patient-days, with geriatric and medical units hit hardest. Up to half of fallers are injured; in older adults, major injuries are ~8× more common, with hip fractures, subdurals, and ICH driving longer LOS, readmissions, cost, litigation, and loss of trust. Add in Joint Commission sentinel event rules and CMS non-payment for fall injuries—and you’ve got a must-fix safety problem.

Then we clean up the language: hospital falls as any unexpected descent to floor/lower level; we sort anticipated physiological (gait, weakness, meds), unanticipated physiological (delirium, new illness, syncope), and accidental (environmental). We walk through injury severity from none → minor → moderate → Major A/B/C → death, and zoom in on high-risk contexts: toileting, bed-exit, transfers, ambulation, peri-procedural.

Next, we hit what’s modifiable in hospital: • Psychotropics and other FRIDs (benzos, antidepressants, antipsychotics, sedatives, opioids, insulin, antihypertensives, high ACB burden) • Orthostatic hypotension, gait/balance deficits, muscle weakness, vision loss • Delirium, sleep disruption, pain, and continence issues • Environmental and care-related factors: clutter, lighting, equipment, staffing, and unsupervised toileting

For screening and risk strat, we ditch scored “fall risk” stickers and lead with brief admission screening (think CDC STEADI 3 questions) plus automatic high-risk flags (recent falls, injury, frailty, gait impairment). Anyone who screens positive gets multifactorial assessment: meds, orthostatics, gait/balance (TUG), cognition/delirium, vision, feet/footwear, continence, ADLs, and environment—using tools like Morse or Johns Hopkins to structure, not replace, clinical judgment.

When a fall happens, we move fast: ABCs, head-to-toe for occult injury, neuro check, hip and spine, orthostatics, targeted labs and imaging. We ask the framing question: “If this were a healthy 20-year-old, would they have fallen?” If not, we hunt for underlying pathology—arrhythmia, infection, stroke, medication toxicity—and loop in PT/OT early.

The core of the episode is the multifactorial bundle: • Medication review & deprescribing FRIDs; reschedule diuretics/antihypertensives away from night • Supervised exercise & mobility: strength, balance, functional training; no “bed rest by default” • Environmental optimization: lighting, clutter, bed height, grab bars, walking aids within reach • Delirium prevention/management: orientation, sleep hygiene, sensory aids, early mobilization • Toileting protocols: scheduled voids, timely assistance, prioritize bathroom & bed-exit safety • Nutrition & vitamin D where indicated • Patient, family, and staff education as a high-yield, low-tech intervention

We zoom in on special populations—very old, cognitively impaired, Parkinson’s, post-op, rehab and ICU patients—where falls are frequent and injuries severe. Here we stress person-centered care, care-partner involvement, sustained exercise, and balancing the tension between mobility and risk aversion.

Then we tackle the controversies: physical restraints, bed/chair alarms, sitters, and high-tech sensors. We review why the evidence shows little benefit and real harm—more delirium, more device removal, more meds, longer stays—and how guidelines are shifting towards least-restraint, engagement-based models instead of “alarm everything.”

We close with the post-fall and QI playbook: standardized post-fall assessment, a quick bedside huddle, unit-level root cause analysis, and using tools like Fall TIPS-style bedside plans to translate risk factors into visible, actionable precautions. We outline how to build a falls bundle into your order sets, nursing flowsheets, handovers, and dashboards so prevention is baked into the system, not bolted on.

Fast, pragmatic, and systems-focused—recognize the modifiable risks, screen smart, build a tailored multifactorial bundle, stop over-relying on restraints and alarms, and treat every fall as a trigger for better design, not blame.

Atrial Flutter for Hospitalists: Master the ECG, Anticoagulation, Critical Distinction from Atrial Fibrillation, and the Ablation Advantage19 Oct 202500:31:09

In this episode of Hospital Medicine Unplugged, we sprint through atrial flutter—spot the sawtooth, choose the fastest safe path to sinus, and keep strokes off the table.

We open with the do-firsts: confirm the rhythm and triage the “why.” Grab a 12-lead ECG—regular narrow tachycardia with classic sawtooth F-waves (atrial ~240–300 bpm, often 2:1 AV → ~150 bpm). Don’t confuse variable conduction with AF. Put the patient on telemetry; replete K/Mg (K ≥4, Mg ≥2). Hunt triggers (infection, hypoxia, decomp HF, stimulants, post-op). Get an echo to size up structure/valves; plan TEE if cardioversion and duration ≥48 h or unknown.

Acute decisions—match stability to action: • Unstable (hypotension, ischemia, pulmonary edema, shock): synchronized cardioversion now. Start 50–100 J biphasic (AP pads), escalate as needed. • Stable: pick rate vs rhythm based on symptoms, duration, and comorbids. – Rate control first line: β-blocker (esmolol/metoprolol) or diltiazem/verapamil; avoid NDHP-CCBs in HFrEF. Add digoxin as adjunct if needed. If decomp HF/hypotension, IV amiodarone can slow the ventricle. – Rhythm control when rate control is tough or symptoms/high stakes: synchronized cardioversion (near-certain success), or ibutilide 1 mg IV over 10 min (give Mg 2 g IV; strict QT monitoring) or dofetilide (inpatient initiation, QT monitoring). Class IC (flecainide/propafenone) can provoke 1:1 conduction—never give without AV-nodal blockade and avoid in structural heart disease. – Pre-excitation (WPW pattern): avoid AV-nodal blockers; urgent cardioversion.

Anticoagulation—same rules as AF: use CHA₂DS₂-VASc for long-term decisions. If duration ≥48 h or unknown, choose ≥3 weeks of therapeutic anticoagulation or TEE-guided cardioversion, and continue OAC ≥4 weeks post-cardioversion. Many hospitalized adults meet OAC criteria—don’t skip stroke prevention.

When to favor rhythm early: persistent rapid rates despite meds, ischemia/HF, poor tolerance, or procedural timing needs. A quick shock back to sinus simplifies everything.

Think definitive: CTI ablation for typical (isthmus-dependent) flutter is >90–95% effective with low risk—strong option after a first significant hospitalization or if recurrent. Expect incident AF (~50%) after flutter—monitor and keep OAC per risk, not just rhythm appearance.

ICU/complex plays: in decompensated HF or shock, cardiovert early; if meds needed, amiodarone is often the hemodynamically friendliest for rate control. Correct hypoxemia, fever, and volume—they’re gasoline on the circuit.

Special populations, quick hits: • HFrEF: β-blocker if stable; avoid diltiazem/verapamil; amiodarone for rate/rhythm if needed; early ablation is attractive. • Post-cardiac surgery: often transient—rate control, consider amiodarone/ibutilide if symptomatic; map/ablate for recurrent cases. • Pre-excited flutter: no AV-nodal blockers; shock or procainamide (if truly stable and expert-guided).

Procedure pearls (make it boring-safe): Anterior–posterior pad placement, sedation ready, sync ON, start low energy (flutter needs less than AF), and re-check rhythm + anticoagulation plan before leaving the bedside.

We close with the system moves: an atrial-flutter bundle that (1) auto-flags sawtooth at ~150 bpm and fires a cardioversion pathway for instability; (2) hard-stops electrolytes to K ≥4/Mg ≥2; (3) blocks NDHP-CCBs in HFrEF and blocks AV-nodal agents if pre-excitation seen; (4) offers ibutilide with QT/Mg guardrails and dofetilide inpatient-initiation checklist; (5) forces TEE-or-≥3-weeks-OAC when duration ≥48 h/unknown, and locks in ≥4 weeks post-CV OAC; (6) auto-consults EP for CTI ablation after first significant admission or recurrence; (7) adds AF-surveillance plan (patch/tele) and leaves OAC tied to CHA₂DS₂-VASc, not wishful thinking.

Fast, ECG-led, and stroke-savvy—see the sawtooth, fix the rate or flip the rhythm, and never miss the anticoagulation.

Atrial Fibrillation Management in Hospitalized Patients: Early Rhythm Control, Ablation, and the 48-Hour Anticoagulation Rule19 Oct 202500:38:31

In this episode of Hospital Medicine Unplugged, we blitz inpatient atrial fibrillation (AF)—fix the trigger, pick rate vs rhythm, and prevent stroke—so you can move fast and safely.

We open with the do-firsts: vitals + hemodynamics, bedside ECG, labs (electrolytes, Mg, CBC, TSH when relevant), pulse oximetry/ABG, and a deliberate hunt for reversible triggers—infection, hypoxia, electrolyte derangements, volume shifts, ACS/PE, surgery, alcohol/withdrawal, stimulants. Treat the cause; the rhythm often follows.

Unstable? (hypotension, shock, ischemia, pulmonary edema) → immediate synchronized DCCV. While prepping: oxygen, gentle fluids/pressors as needed, avoid AV-nodal blockers if WPW suspected.

Stable? Rate or rhythm are both reasonable. • Rate control first for most: β-blocker (metoprolol, esmolol) or non-DHP CCB (diltiazem) if LVEF >40%. Add digoxin when hypotensive/sedentary/HFrEF. Target lenient HR <110 at rest; go stricter if symptoms or TIC (tachycardia-induced cardiomyopathy). • Rhythm control when symptoms persist, HF decompensation, poor rate control, newly diagnosed AF with CV risk, or patient preference. Options: electrical cardioversion (fast, effective), or drugs tailored to substrate: Class Ic (flecainide/propafenone) only if no structural/ischemic disease; amiodarone for structural heart disease/HF; sotalol/dofetilide (inpatient initiation, watch QT/renal). Early rhythm control can lower CV events in selected patients. • HFrEF tips: favor β-blocker ± digoxin for rate; avoid diltiazem/verapamil; consider catheter ablation early for symptom control and outcomes.

Cardioversion anticoagulation rules (no preexcitation/WPW): • AF >48 h or unknown: ≥3 weeks therapeutic OAC or perform TEE-guided cardioversion if no LA thrombus, then ≥4 weeks OAC after. • AF <48 h and low stroke risk: may cardiovert now; still continue OAC for ~4 weeks if risk factors exist.

Stroke prevention—don’t miss it. Use CHA₂DS₂-VASc to guide therapy; check HAS-BLED to modifiable risks—not to deny needed OAC. Prefer DOACs over warfarin for most nonvalvular AF (dose-adjust for renal function). Warfarin for mechanical valves or moderate–severe mitral stenosis. In sepsis, avoid routine acute anticoagulation (↑bleeding, no stroke benefit). LAAO is a niche option when long-term OAC is truly not possible.

Post-op AF (CABG/valve): β-blockers first; rhythm control (amiodarone or DCCV) if poorly tolerated; consider OAC for ~6–8 weeks if bleeding risk acceptable, then reassess. Pregnancy: DCCV is safe; for rate use β-blocker (not atenolol) or digoxin. Heparins preferred for anticoagulation; DOACs are avoided.

We close with the hospital bundle that sticks:

  1. Screen & treat triggers (sepsis, hypoxia, electrolytes, ACS/PE, meds).

  2. Default to rate control (β-blocker or diltiazem; digoxin add-on) with HR <110 unless symptomatic.

  3. Escalate to rhythm control for symptoms, HF, or failure of rate—DCCV early; pick AA drug by substrate; consider ablation in HFrEF or recurrent.

  4. Anticoagulation pathway: DOAC-first, valve disease exceptions; TEE vs 3-week rule before cardioversion; ≥4 weeks after.

  5. Monitoring: telemetry, daily K/Mg goals (K ≥4.0, Mg ≥2.0), watch QT/AV block, drug-drug interactions.

  6. Risk-factor remix: weight loss, BP control, OSA treatment (CPAP), diabetes optimization, alcohol moderation, exercise, smoking cessation—these cut AF burden and recurrences.

  7. Discharge plan: clear OAC plan, rate/rhythm meds with doses, red-flags, follow-up ECG/Holter, renal/hepatic labs for drug safety, and referral to AF clinic when available.

Bottom line: Treat the trigger, stabilize the rate, choose rhythm wisely, and anticoagulate by risk. Build a system that’s fast, safe, and recurrence-proof—so your patients leave in rhythm (or with a controlled rate) and a plan that lasts.

Hepatorenal Syndrome (HRS-AKI) in Hospitalized Patients: Navigating the Razor-Thin Margin of Survival in Cirrhosis—New Guidelines, Albumin, and the Transplant Bridge19 Oct 202500:30:46

In this episode of Hospital Medicine Unplugged, we sprint through hepatorenal syndrome–AKI (HRS-AKI)—exclude look-alikes fast, start albumin + vasoconstrictor early, watch the lungs, and loop in transplant.

We open with the do-firsts: clinical diagnosis by exclusion—rule out hypovolemia, nephrotoxins, structural kidney disease. Pull diuretics/ACEi/NSAIDs, check UA/sediment (should be bland), kidney US (should look normal), and hunt triggers (SBP, GI bleed, overdiuresis). Albumin challenge (≈1 g/kg/day, max 100 g for 24–48 h): no renal improvement → HRS-AKI. Urine biomarkers (e.g., NGAL) may help ATN vs HRS but aren’t ready for routine.

Call AKI early using ICA criteria: ↑Cr ≥0.3 mg/dL/48 h or ≥1.5× baseline/7 d and/or low urine output. Don’t chase urine Na/FeNa alone (diuretics confound). Treat the precipitant (especially SBP: antibiotics + albumin).

Treatment—build the hemodynamic fix: • Albumin is adjunct, not a cure: after the initial challenge, continue 20–40 g/day with vasoconstrictor. • First-line vasoconstrictor: terlipressin (now FDA-approved) + albumin. Dosing: 0.5–2 mg IV q6h or continuous infusion; up to 14 days. Stop early if <25% Cr fall by day 4 at max tolerated dose. • Safety watch: respiratory failure/pulmonary edema risk—avoid large albumin loads, hold if SpO₂ <90%, be cautious in advanced ACLF or cardiopulmonary disease. • Validated alternative: norepinephrine (ICU, central line). Evidence supports noninferior HRS reversal and sometimes fewer AEs—great in shock or when terlipressin is contraindicated. • If IV agents unavailable: midodrine + octreotide + albumin (inferior; use only as a fallback).

Special plays & edge cases: • ACLF: higher grade → lower response, higher risk—expedite transplant evaluation. • Volume overload on therapy: down-titrate/hold albumin, reassess with POCUS (IVC/B-lines), pause terlipressin if hypoxemia. • SBP: treat and give albumin (1.5 g/kg day 1, 1 g/kg day 2) to prevent kidney failure. • RRT: bridge to liver transplant or for life-threatening indications; limited benefit in non-candidates—align with goals of care. • Transplant is the only definitive cure; consider SLK in persistent renal dysfunction.

Monitoring that matters: • Daily Cr, UOP, weights, electrolytes, oxygenation; infection surveillance. • Track congestion (exam + POCUS), and de-escalate albumin if lungs load up. • Define response (Cr to near-baseline); nonresponse by day 4 → switch strategies.

Medication pitfalls you don’t want to meet: • Over-infusing albumin → pulmonary edema. • Delaying vasoconstrictors waiting for full “workup.” • Using midodrine/octreotide first when IV options exist. • Stopping early despite improving Cr; or continuing blindly past day-4 nonresponse.

We close with the HRS bundle that sticks: (1) Exclude hypovolemia/nephrotoxins/structural disease fast; (2) Albumin challenge (24–48 h) → if no improvement, start vasoconstrictor + albumin; (3) Prefer terlipressin, use norepinephrine in ICU/shock or contraindications; (4) Hard stop/check at day 4 for response; (5) Prevent/ treat SBP (antibiotics + albumin); (6) Protect the lungs—watch SpO₂, CXR/POCUS, adjust albumin; (7) Early transplant activation ± RRT as bridge; (8) Multidisciplinary liver–kidney–ICU collaboration.

Bottom line: HRS-AKI is a race against time—diagnose by exclusion, pair albumin with the right vasoconstrictor, watch for respiratory hits, and escalate to transplant pathways early.

Cardiorenal Syndrome in the Hospitalized Patient: Targeting Venous Congestion and Pseudo-AKI with the VeXUS Protocol19 Oct 202500:42:46

In this episode of Hospital Medicine Unplugged, we blitz cardiorenal syndrome (CRS)—define fast, subtype smart, decongest early, protect kidneys, and tighten the cardio–nephro handshake.

We start with the frame: CRS = bidirectional heart–kidney dysfunction where trouble in one organ triggers or worsens the other. Know the five plays: Type 1 (acute cardiorenal), Type 2 (chronic cardiorenal), Type 3 (acute renocardiac), Type 4 (chronic renocardiac), Type 5 (secondary/systemic). Classification isn’t trivia—it drives workup and therapy.

Pathophys in one breath: venous congestion > low forward flow; RAAS/SNS surge, vasopressin, inflammation & endothelial dysfunction; sodium avidity → diuretic resistance. CKD stacks the deck toward higher mortality and rehospitalization.

Bedside diagnosis—do-firsts and don’t-miss: • History + trend the eGFR, meds, and prior decompensations. • UA + urine sediment to rule intrinsic renal disease; check albuminuria/proteinuria. • BNP/NT-proBNP, Cystatin C for risk; watch electrolytes, BUN/Cr. • TTE for LV/RV function and filling pressures; consider renal US/Doppler and VeXUS POCUS for systemic congestion; CMR selectively. • True AKI vs pseudo-AKI: a small creatinine rise during effective diuresis can reflect hemoconcentration, not injury—don’t abort decongestion if the patient is clinically improving.

Risk & admit cues: refractory hypoxemia, rising JVP/edema, oliguria, shock/low MAP, refractory hyperK/acidosis, suspected Type 1 or 3 CRS, or diagnostic uncertainty.

Treatment—make decongestion the north star: • First-line: IV loop diuretic (adequate dose & frequency) with daily weights, I/O, urine Na, and electrolyte/renal panels. Aim for complete decongestion. • If resistance hits: sequential nephron blockade (add thiazide-type), consider MRA when safe, and natriuresis-guided up-titration. • Vasodilators/afterload reduction for high filling pressures with preserved BP; inotropes for low-output states or shock—short and targeted. • SGLT2 inhibitors & RAAS blockade: recommended in HF; initiate/continue with renal vigilance and pause only for hypotension, hyperK, or true AKI. • Refractory congestion: ultrafiltration, peritoneal dialysis, or acute RRT—select carefully and match removal rate to plasma refill. • Devices: consider CRT for dyssynchrony and mechanical circulatory support in advanced cases—heart help can be kidney help.

Monitoring that matters: • Trend congestion (exam, weights, VeXUS, echo signs), urine output/Na, and CR/BUN/electrolytes. • Expect and accept permissive creatinine bumps if hemodynamics and volume status are improving. • Reassess daily: diuretic plan, RAAS/SGLT2 status, K/Mg, and hemodynamics (noninvasive first; invasive if shock/ambiguity).

Etiology threads—treat the cause: • Sepsis (Type 5): source control + hemodynamics. • Renal-first hits (Type 3/4): correct nephrotoxins, ischemia, or GN; manage afterload/arrhythmias. • Cardiac-first (Type 1/2): guideline-directed HF therapy with congestion-first strategy.

Pitfalls to dodge: underdosing loops, stopping diuresis for mild Cr rise, ignoring RV failure/venous hypertension, delayed escalation to combo diuretics/UF, and premature RAAS/SGLT2 withdrawal without a clear reason.

We close with the hospital CRS bundle that sticks:

  1. Classify type (1–5) and rule intrinsic kidney disease (UA/sediment, albuminuria, renal US).

  2. Default to loop + natriuresis-guided titration; add thiazide-type early for resistance; consider MRA.

  3. Track congestion multimodally (exam + weights + VeXUS ± TTE).

  4. Guard rails: daily labs, K/Mg repletion, renal & hemodynamic checks.

  5. RAAS/SGLT2 smart use—continue/initiate when safe; hold for hypotension, hyperK, true AKI.

  6. Escalation pathway: UF/RRT for refractory overload or life-threatening derangements; CRT/MCS in select HF.

  7. Team sport: cardiology + nephrology + ICU/pharmacy from day one; discharge with diuretic plan, labs, and early follow-up.

Bottom line: Congestion kills kidneys—decongest completely, use RAAS/SGLT2 wisely, monitor like a hawk, and move fast together.

Mallory-Weiss Tears in Hospitalized Patients: Identifying the High-Stakes Bleeders and Mastering Mechanical Hemostasis17 Oct 202500:26:48

In this episode of Hospital Medicine Unplugged, we cut through the Mallory-Weiss tear—spot it fast, stop the bleed, stabilize smart, and endoscope right.

We open with the why and who: a longitudinal mucosal laceration at the gastroesophageal junction, triggered by vomiting, retching, or sudden pressure surges. Alcohol, reflux esophagitis, hiatal hernia, NSAIDs, coagulopathy, and liver disease stack the odds. It’s uncommon but not benign—~7.5/100,000 hospitalized patients, with a small but high-risk subset landing in the ICU.

Presentation pearls: classic sequence—retching then hematemesis—appears in <1/3 of cases. Hematochezia or shock = severe bleed. Keep an eye on cirrhotics, dialysis patients, and the elderly—they hide blood loss until they crash.

Diagnosis: stabilize first, scope early. EGD within 24 hours confirms the tear and rules out ulcers, varices, or Dieulafoy’s lesion. Imaging? Rarely needed unless endoscopy fails or perforation’s on the table.

Stabilization priorities: • 2 large-bore IVs, crystalloids, restrictive transfusion (Hgb <7 g/dL unless cardiac or massive bleed). • Reverse coagulopathy; correct platelets >50k, fibrinogen >120 mg/dL in liver disease. • Airway protection if vomiting or altered. • ICU admission for shock, cirrhosis, or hemodialysis.

Endoscopic game plan—mechanical first: • Band ligation or hemoclips = best-in-class. Both achieve >95% hemostasis with minimal recurrence. • Epinephrine injection is for temporary control—never solo for spurting bleeds. • Combination therapy (epi + clip) works when mechanical access is tough. • Nonbleeding tears? Observe, hydrate, PPI, discharge early if stable. • If all fails—angiographic embolization or surgery (rarely needed).

Medical and supportive backbone: • High-dose IV PPI → oral PPI transition once stable. • Hold NSAIDs, antiplatelets, anticoagulants unless high thrombotic risk. • Monitor for anemia, AKI, sepsis, and rebleeding. • Refeed early in stable, nonbleeding patients—delays don’t help.

Special populations: • Cirrhosis or coagulopathy: correct deficits, early endoscopy, and antibiotics if variceal source uncertain. • Hemodialysis: gentle fluids, watch for overload, early scope. • Massive bleeds: resuscitate, scope fast, consider mechanical endoscopy or TAE (transarterial embolization) if refractory.

Complications: bleeding anemia (26%), shock (3%), AKI, sepsis, and rare death (~2–3%). Rebleeding 2–12%, mostly in coagulopathic or cirrhotic patients. Prognosis: excellent for most; poor in the elderly, cirrhotics, and those with shock.

Prevention & long game: • Manage reflux, cut alcohol, stop NSAIDs. • PPI prophylaxis for high-risk inpatients or post-bleed. • Helicobacter pylori eradication if present. • Multidisciplinary care = fewer readmissions, shorter stays, and safer outcomes.

We close with the system moves: (1) Early EGD protocol for all upper GI bleeds. (2) Restrictive transfusion + airway safety bundle. (3) Mechanical-first endoscopic pathway (band or clip). (4) ICU triage for cirrhosis/dialysis/shock. (5) Post-bleed PPI and risk-factor modification. (6) Track hemoglobin + rebleed signs before discharge.

Fast scope, tight stabilization, and mechanical mastery—that’s how you keep Mallory-Weiss tears from turning catastrophic.

Inpatient Management of Portal Hypertension: Decompensation and the Preemptive TIPS Revolution in Hospitalized Patients17 Oct 202500:26:05

In this episode of Hospital Medicine Unplugged, we tackle portal hypertension in hospitalized cirrhosis—find it fast, control bleeding, dry the belly, clear the brain, and pick the right patients for TIPS and transplant.

We open with the diagnosis play: suspect it in cirrhosis with splenomegaly/ascites/varices. Gold standard is HVPG; CSPH = ≥10 mmHg. In real life, lean on liver stiffness + platelets for risk (rule-in ≥25 kPa or rule-out <20 kPa with high platelets), and confirm with varices on endoscopy or collaterals on imaging.

When blood hits the basin—acute variceal bleed—move fast: • Do first: large-bore access, type & cross, start vasoactive agent immediately (octreotide/terlipressin), give prophylactic IV antibiotics—prefer ceftriaxone, and restrict transfusion to Hgb ~7 g/dL (unless extenuating). • Endoscopy with band ligation within 12–24 hours. • Early TIPS for the high risk: Child-Pugh C ≤13 or Child-Pugh B with active bleeding, or if endoscopy/meds fail. This cuts rebleeding and improves survival. • Avoid routine plasma/platelets; correct coagulopathy only for procedures or active bleeding.

Between bleeds, prevent the next one: • Primary prophylaxis: NSBBs (propranolol, nadolol, carvedilol preferred for large varices) or banding if NSBB-intolerant. • Secondary prophylaxis: combo NSBB + band ligation after a bleed.

Ascites management that sticks: • Sodium <2 g/day. • Diuretics: spironolactone + furosemide, titrate carefully. • Large-volume paracentesis for tense/refractory ascites with albumin replacement. • Consider TIPS for refractory ascites in appropriate candidates. • Watch for hyponatremia and renal injury—dose-adjust and protect the kidneys.

Encephalopathy, SBP, and kidneys: • HE: find triggers, lactulose to 2–3 soft stools/day, add rifaximin for secondary prevention. • SBP: ceftriaxone plus IV albumin (1.5 g/kg day 1, 1 g/kg day 2); consider secondary prophylaxis after recovery. • HRS-AKI: albumin + vasoconstrictor (terlipressin or norepinephrine), catheterize to trend UOP; evaluate for TIPS in select cases and early transplant referral.

Imaging & surveillance you shouldn’t skip: • US with Doppler to look for portal vein thrombosis and to screen for HCC (pair with AFP per local protocol). • Endoscopic surveillance individualized by risk and noninvasive markers rather than one-size-fits-all scopes.

Who gets a shunt (and who doesn’t): • TIPS controls bleeding and ascites—great in the right patient, risky in the wrong one. Beware high MELD, severe liver failure, or significant cardiac disease (relative/absolute contraindications). Monitor post-TIPS for encephalopathy and shunt dysfunction.

Medication & system pitfalls: • Don’t over-transfuse—it raises portal pressure. • Start ceftriaxone early in variceal bleed. • Carvedilol can drop BP—titrate to tolerance. • Albumin after paracentesis when >5 L removed. • Avoid nephrotoxins (NSAIDs, IV contrast when possible). • Build order sets: vasoactive + antibiotic bundle for bleed, CRP/renal checks, and a TIPS early-evaluation pathway for high-risk bleeders.

We close with the big picture: portal hypertension is the engine of decompensation—catch it, treat bleeds aggressively, use NSBBs/banding wisely, control ascites, and pull the TIPS lever early in the patients who benefit. And never forget the destination for many: timely transplant evaluation once major-index complications appear.

Acute Upper GI Bleeding (UGIB) in Hospitalized Patients: Mastering the Critical First Hours of Hematemesis Management for Hospitalists16 Oct 202500:31:27

In this episode of Hospital Medicine Unplugged, we blitz acute peptic ulcer bleeding—risk fast, resuscitate right, scope within 24 hours, secure hemostasis, run high-dose PPIs, and crush recurrence.

We open with the do-firsts: airway/breathing/circulation, 2 large-bore IVs, orthostatics, urine output, type & cross, and labs (CBC, BMP, INR/LFTs). Risk-stratify with Glasgow–Blatchford (GBS)—≤1 may go outpatient; everyone else is inpatient/urgent care.

Resuscitation that matters: balanced crystalloids, permissive targets while bleeding, and a restrictive transfusion strategy (Hb <7–8 g/dL; <10 g/dL if active CAD). Correct coagulopathy pragmatically; reverse only when it changes decisions.

Pre-endoscopic moves: start IV PPI immediately, consider IV erythromycin 250 mg 30–60 min pre-EGD to clear the field. No tranexamic acid. If cirrhosis/portal hypertension is on the table: prophylactic antibiotics + vasoactive therapy.

Endoscopy: within 24 hours after stabilization; sooner if unstable once perfusing. Treat high-risk stigmata (Forrest Ia/Ib/IIa/IIb): • Dual-modality is king—epinephrine + thermal or mechanical clips. • Over-the-scope clips (OTSC) and hemostatic powders are clutch for difficult or diffuse bleeding. • No therapy for clean base/flat spot; discharge planning starts now.

Post-EGD pharmacotherapy—build the acid-suppression backbone: • High-dose PPI for 72 h: 80 mg IV bolus → 8 mg/h infusion or 40–80 mg IV/PO BID. These regimens are equivalent. • Then step down: most get daily PPI; high-risk get BID x 10–14 days, then daily 2–4 weeks.

Monitoring & rebleeding: watch vitals q2–4h, H/H q6–12h for 24–48h, and the stool/NG story. Rebleed? → repeat endoscopy first. If failure or early re-rebleed, transcatheter arterial embolization; surgery if IR/EGD fail.

Etiology plays—prevent the encore: • H. pylori: test everyone (biopsy/stool/UBT), treat 14 days, confirm eradication off PPI (≥2 weeks) and antibiotics/bismuth (≥4 weeks). • NSAID/aspirin ulcers: stop the culprit when possible. If needed, switch to COX-2 + daily PPI. For secondary prevention, resume aspirin early after hemostasis. • Idiopathic ulcers: high-dose PPI 6–8 weeks, scrutinize meds/comorbidities, close follow-up.

Antithrombotics without fear: • Aspirin for secondary prevention—continue or restart early; mortality benefit outweighs modest rebleed risk. • Warfarin/DOACs: hold during active bleed; reverse selectively for life-threatening hemorrhage; restart promptly after hemostasis based on thrombotic risk (coordinate with cardiology/hematology).

Nutrition, level of care, disposition: early feeding after control is safe and shortens LOS. Step-down/ICU for major stigmata or instability (first 24 h). Low-risk ulcers can go home early with clear return precautions and a PPI plan.

Medication pitfalls you don’t want to meet: epinephrine monotherapy (never), under-dosed PPIs, premature endoscopy before resuscitation, and stopping secondary-prevention aspirin without a plan.

We close with the systems bundle that sticks:

  1. Triage with GBS + ABCs + IV PPI ± erythromycin;

  2. EGD ≤24 h with dual-modality for high-risk stigmata; OTSC/powders for select cases;

  3. 72-hour high-dose PPI (infusion or BID—equivalent), then tailored step-down;

  4. Rebleed pathway: repeat EGD → IR embolization → surgery if needed;

  5. Etiology track: test/treat/confirm H. pylori, NSAID strategy, idiopathic high-dose PPI;

  6. Antithrombotic game-plan: early aspirin for secondary prevention, timely anticoagulant resumption;

  7. Early enteral nutrition, targeted monitoring, and clear discharge instructions.

Fast, hemostasis-focused, and recurrence-proof—stabilize, scope, suppress acid, fix the cause, and never miss a rebleed.

Peptic Ulcer Bleeding in the Hospitalized Patient: From Emergency Resuscitation to the 72-Hour PPI Mandate and Anticoagulation Balancing Act16 Oct 202500:40:41

In this episode of Hospital Medicine Unplugged, we take on acute peptic ulcer bleeding (PUB)—triage fast, stabilize smart, scope early, seal the vessel, and lock in acid suppression + secondary prevention.

We start at the door with risk stratification: use the Glasgow–Blatchford Score (GBS)—≤1 means very-low risk and potential outpatient management; everyone else gets admitted and prepped for urgent endoscopy. Pull CBC, chemistries, INR, type & cross.

Resuscitation that helps, not harms: large-bore IVs, balanced crystalloids, and a restrictive transfusion strategy—transfuse at Hgb <7–8 g/dL (consider <10 g/dL in active coronary disease). Aim for hemodynamic stability before the scope. Early enteral feeding once controlled shortens LOS.

Pre-endoscopic moves: start IV PPI immediately; give IV erythromycin pre-scope to clear the stomach (better visualization). Skip tranexamic acid. If the patient has cirrhosis, flip to the variceal bundle (antibiotics + vasoactive agents) while you clarify source.

Endoscopy timing & targets: perform within 24 hours (earlier only after stabilization in the unstable). Treat high-risk stigmata—active bleeding, non-bleeding visible vessel, adherent clot. Use dual-modality therapy (epi injection + thermal or clips) as your default. Deploy OTSC or hemostatic powder for difficult lesions or poor visualization. Clean base/flat spots? No therapy; plan early discharge.

Post-endoscopic pharmacotherapy (the acid wall): run high-dose PPI for 72 hours—either 80 mg IV bolus → 8 mg/h infusion or intermittent high-dose IV/PO (equally effective). Then step down: once-daily PPI for most; BID for 10–14 days in high-risk, then daily 2–4 weeks.

Monitoring & rebleeding rescue: watch closest in the first 72 hours—vitals, H/H every 6–12h, stool color, symptoms. Suspect rebleed? Resuscitate → repeat endoscopy (works ~75%). If bleeding persists, escalate to transcatheter arterial embolization (TAE); surgery if IR/endoscopy fail.

Etiology matters (prevent the sequel): • H. pylori: test everyone, eradicate if positive, and confirm cure (breath/stool ≥4 wks post-abx; off PPI ≥2 wks). Eradication slashes recurrence to near-zero. • NSAID/aspirin ulcers: stop NSAIDs; if indispensable, switch to COX-2 + PPI. For secondary-prevention aspirin, resume within 1–7 days post-hemostasis (cardiology input for DAPT). • Idiopathic ulcers: higher recurrence—longer PPI course (6–8 wks) and tight follow-up.

Antithrombotics without chaos: hold during active bleed, but restart early after hemostasis to avoid thrombotic events—continue/restart aspirin for secondary prevention and reintroduce anticoagulants promptly based on thrombotic risk (multidisciplinary call). Use PCC/vitamin K or specific DOAC reversal only for life-threatening bleeds.

Discharge playbook: • Low-risk endoscopic findings → early discharge with clear return precautions. • High-risk stigmata → observe ≥72 h with high-dose PPI, then taper. • Educate on red flags (melena, hematemesis, syncope), ensure H. pylori test-of-cure, review meds, and consider iron for anemia.

Bottom line: assess risk fast, resuscitate right, endoscope within 24h, use dual-modality hemostasis, and run high-dose PPI for 72h. Then fix the cause (H. pylori, NSAIDs, antithrombotics) to prevent the rematch.

Diverticulitis in Hospitalized Patients: The New Evidence on Antibiotics, Abscess Drainage, and Who Needs Surgery16 Oct 202500:33:40

In this episode of Hospital Medicine Unplugged, we blitz acute diverticulitis—spot it early, stage it right, treat what matters, and prevent the encore.

We open with the why: ~200,000 US admissions/year and >$6.3B in costs. Risk stacks with age >65, obesity, NSAIDs/steroids/opioids, HTN/DM2, connective-tissue disease, and genetics. Patients roll in with LLQ pain, fever, leukocytosis, N/V.

Do-firsts in the ED/ward: IV access, analgesia (acetaminophen first; minimize opioids; avoid routine NSAIDs), antiemetics, IV fluids, and labs (CBC, BMP, UA, CRP). CT A/P with IV contrast is the diagnostic gold standard—~99–100% sensitivity/specificity—to confirm diverticulitis and flag complications.

Call the type: • Uncomplicated = localized inflammation, no abscess/perf/fistula/obstruction. • Complicated = any abscess, perforation, fistula, obstruction/stricture, peritonitis.

Who needs a bed? Admit for complicated disease, high fever (>38.5°C), marked leukocytosis, can’t tolerate PO, immunosuppression, serious comorbidity, or no home support. Outpatient is reasonable for low-risk, imaging-confirmed uncomplicated cases with reliable follow-up.

Treatment—build the supportive core: • Bowel rest → advance diet as tolerated in 2–3 days. • Antibiotics are not routine for all uncomplicated cases; reserve for high-risk (elderly, immunocompromised, persistent fever/WBC, severe comorbidity, pregnancy). • If antibiotics needed: IV ceftriaxone + metronidazole or ampicillin/sulbactam; step down to orals when improving. Typical 4–7 days (uncomplicated needing abx); 7–14 days (complicated)—tailor to response and source control.

If the core buckles—manage complicated disease: • Abscess <3 cm: IV antibiotics alone. • Abscess ≥3 cm: Percutaneous drainage + IV antibiotics (success up to ~80%). • Generalized peritonitis, failed drainage, obstruction, or clinical deterioration: Urgent surgical consult; consider resection ± primary anastomosis vs Hartmann based on stability. • Re-image at 48–72 h if no improvement.

Special populations you won’t want to miss: • Elderly: lower threshold for CT; antibiotics more often indicated; individualize operative decisions. • Immunocompromised: always treat with antibiotics, admit liberally, and involve surgery early; higher risk of rapid progression despite mild exam.

Complication radar: abscess/phlegmon, perforation/peritonitis, fistula (look for pneumaturia/fecaluria), obstruction/stricture, bleeding, sepsis/AKI. Risk rises with CRP >140 mg/L, WBC >15 ×10⁹/L, extraluminal air/fluid on CT, long inflamed segment, and major comorbidity.

Colonoscopy after the dust settles: • Complicated diverticulitis: schedule 6–8 weeks post-resolution (unless a high-quality colonoscopy was done within a year and no alarm features). • Uncomplicated: individualized—consider prior screening and symptoms; investigate early for alarm signs (weight loss, anemia, bleeding, change in caliber, persistent pain).

Secondary prevention that sticks: • High-fiber, plant-forward diet, physical activity, weight optimization, avoid tobacco, and limit chronic NSAIDs (keep aspirin for CAD when needed). • No routine mesalamine, probiotics, or rifaximin—evidence doesn’t support them. • Elective surgery isn’t about episode counting; decide based on severity, smoldering symptoms, fistula/stricture, and patient goals.

We close with the diverticulitis bundle: (1) confirm with contrast CT; (2) supportive care first (fluids, pain control, diet advance); (3) selective antibiotics—don’t overuse; (4) drain abscess ≥3 cm; (5) call surgery for peritonitis/obstruction/failed nonop care; (6) reassess at 48–72 h, re-image if stalled; (7) plan post-acute colonoscopy (complicated: 6–8 weeks); (8) lock in lifestyle prevention.

Imaging-led, selective with antibiotics, decisive with source control—treat what’s complicated, spare what isn’t, and keep patients out of the readmit loop.

Acute Variceal Bleeding in the Hospitalized Patient: The Critical 3-Step Protocol, Restrictive Resuscitation, and Why Early TIPS is a Game Changer for High-Risk Patients16 Oct 202500:26:19

In this episode of Hospital Medicine Unplugged, we dive into acute variceal bleeding—a high-stakes emergency in cirrhotic patients where seconds count and outcomes hinge on rapid, coordinated care.

We start with the crash course in recognition and stabilization: ICU-level monitoring, two large-bore IVs, and cautious transfusion—targeting a hemoglobin around 7 g/dL to avoid portal pressure spikes and rebleeding. Protect the airway early; intubate if hematemesis or encephalopathy loom.

Pharmacologic therapy doesn’t wait for endoscopy. Hit fast with octreotide (50 μg bolus → 50 μg/h infusion) or terlipressin/somatostatin if available, and start ceftriaxone 1 g IV daily to cover against bacterial translocation and sepsis. These moves—simple but evidence-based—slash early mortality and infection risk.

Then comes the endoscopic moment: perform urgent EGD within 12 hours. Band the culprit—endoscopic variceal ligation (EVL) is first-line for esophageal varices, while cyanoacrylate injection (± coils) dominates for gastric or ectopic sites. Visualization gets a boost from IV erythromycin pre-procedure. If bleeding laughs in your face—bridge with balloon tamponade or self-expanding stent while prepping for TIPS.

TIPS saves lives when all else fails or when the odds are stacked: Child-Pugh C (10–13) or B >7 with active bleeding—go early (within 24–72 hours). It decompresses the portal system, quells refractory bleeding, and buys survival time.

Once the storm calms, secondary prophylaxis takes over. Combine nonselective beta-blockers (carvedilol preferred at 12.5 mg daily) with repeat EVL every 2–4 weeks until varices vanish. No monotherapy—combo therapy halves rebleeding and boosts survival. For gastric or ectopic varices, keep repeating glue injection or move to BRTO or TIPS if anatomy and expertise allow.

Avoid the traps: • Overtransfusion—raises portal pressure. • Routine plasma/platelet correction—no proven benefit. • Early steroid use or unguarded sedation—risk spirals fast.

Complications hit early and hard—shock, infection, encephalopathy, AKI, and early rebleeding top the list. Six-week mortality can reach 40% in advanced cirrhotics, but drops sharply with prompt vasoactive therapy, antibiotics, and endoscopic control.

Predict death early: Child-Pugh C, MELD ≥19, active bleeding at endoscopy, transfusion >4 units, or renal/hepatic failure—each turns the curve downward. These patients may benefit from pre-emptive TIPS and aggressive ICU support.

Special plays: • GOV1 (lesser curvature) → treat like esophageal varices (EVL). • GOV2/IGV1 (fundal) → cyanoacrylate injection ± coil; consider BRTO if available. • Ectopic varices → tailored endoscopic or radiologic therapy. • Non-cirrhotic portal hypertension (e.g., splenic vein thrombosis) → definitive fix may be splenectomy or stenting.

We close with the system bundle that keeps patients alive: (1) Early airway + restrictive transfusion; (2) Immediate vasoactive + antibiotic therapy; (3) Urgent endoscopy (<12 h); (4) TIPS within 72 h for high-risk; (5) NSBB + EVL combo for secondary prevention; (6) Multidisciplinary follow-up with hepatology, radiology, and ICU care.

Rapid, protocolized, and team-driven—control the bleed, decompress the pressure, and protect the liver. This is how you turn variceal crisis into survival.

© My Podcast Data · Projet indépendant · Données issues d'Apple & Spotify
Hospital Medicine Unplugged - Roger Musa MD and Eric Bachrach MD